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Nanoplatforms have considerable potential for delivery of biomedical agents, so as to 
overcome inherent limitations of small molecule drugs or contrast agents, such as fast 
degradation, aggregation and lack of targeting ability. In this dissertation, we demonstrate 
improved imaging and therapy techniques using polyacrylamide (PAA) based 
nanoparticles (NPs) and star-shaped polyethylene glycol (PEG) platforms for cancer and 
cardiac arrhythmia treatment. The proposed albumin conjugated PAA NPs provided 
strong fluorescence and photoacoustic intensities for the Indocyanine Green (ICG) 
contrast agent for use in cancer imaging.  These protein hybrid NPs not only enhanced 
the chemical stability of ICG but also showed in vitro cancer cell specificity, with the 
help of targeting moieties. We also developed methylene blue (MB) conjugated PAA 
NPs for photodynamic therapy (PDT). Its reactive oxygen species (ROS) productivity 
was enhanced by utilizing longer cross-linker than in previous PAA NPs and a newly 
designed microfluidic device contributes to faster tests on the cell killing efficacy of 
photo-drug NPs. Lastly, Chlorin e6 (Ce6) and cardiac targeting peptide (CTP) were 
conjugated to 8-arm PEG for extremely small sized nanoplatforms (CTP‒Ce6‒PEG); it 
showed great potential for treating cardiac arrhythmia by PDT, demonstrating selective 
ablation of arrhythmia causing myocyte cells. Overall, this dissertation, reporting on 
biomedical imaging and therapy based on nanotechnology, shows their potentialities 
towards further modifications for clinical usage and commercialization, not only for 






1.1 Nanoplatforms for Biomedical Applications 
Heart disease and cancer are the first and second most common causes of death in the 
United States. [1] To save the lives of patients, accurate diagnosis, based on suitable 
analyzing methods, and corresponding appropriate treatments are required. Every year, 
new drugs and detection methods are developed to manage these diseases, but many 
people are still afflicted. For better analysis and treatment of diseases, many biomedical 
scientists seek to improve the precision of drug delivery, targeting specific areas and 
precise time. [2] Nanotechnology (an interdisciplinary research regarding fabrication of 
nano-scaled substances, based on chemistry, physics, biology, medicine, engineering, etc.) 
has recently been extensively utilized to develop purposeful designs of nano-sized 
platforms (nanoplatforms) for the precise delivery of biomedical agents. [3,4] The 
nanoplatform is a nano-sized particle, supramolecule, or combination thereof, that 
delivers drugs, contrast agents or itself as a therapeutic/imaging agent to a targeted 
biological domain. It may have a variety of shapes, as long as all dimensions are at least 
in the nanometer size. Until now, the nanoplatforms, such as organic nanoparticles (NPs), 
inorganic NPs, and single-walled carbon nanotubes (SWNTs), etc., have been studied so 
as to enhance efficiency, efficacy, sensitivity and selectivity for diagnostic, sensing, 




To be a successful nanoplatform for biomedical applications, there are several 
specific requirements. [8] First, the size of the nanoplatform should be adjustable, 
depending on the purpose and targeted organ. Second, the surface of the nanoplatform 
should be versatile enough to modify drugs or imaging contrast agents with targeting 
moieties for selective targeting. Third, the nanoplatform should be able to be easily 
controlled with regard to both the initial drug loading amount and the subsequent release 
rate of the loaded drug into the target area. Fourth, the nanoplatforms must be nontoxic 
and biocompatible in order to decrease potential side effects and increase tolerance for 
varying dosages of the drug. Lastly, the synthetic method of preparation should be simple 
and amenable for mass production with good quality control and low cost.  
During the last two decades, the Kopelman group has investigated mainly two 
different types of nanoplatforms, including polyacrylamide (PAA) hydrogel NPs, 
silica/organically modified silica (Ormosil) NPs which are a frequently used as promising 
nanoplatforms for biomedical sensing, imaging and therapeutic purposes. [9-16] PAA 
NPs are nano-sized 3-dimensionally cross-linked polyacrylamide networks containing a 
large amount of water and are synthesized by the reverse micelle polymerization of an 
acrylamide monomer with other functional monomers and cross-linkers. [8] During the 
radical polymerization, the acrylamide, other monomers and cross-linkers are 
polymerized by a water soluble initiator. The size of these NPs is determined by the size 
of the micelle (water-in-oil). The appropriate kind and amount of biocompatible 
surfactant mixture (Brij 30 and AOT), which have both hydrophilic and hydrophobic 
groups at each end of the molecular chain, form a nano-sized aqueous micelle structure in 




following polymerization, the polyacrylamide is not toxic anymore, and non-polymerized 
acrylamides are washed out with surfactants during multiple washing steps. [15,18] The 
PAA NPs are very versatile and can be easily engineered to meet various purposes of the 
application. For example, through copolymerization with a pH or temperature sensitive 
monomer, the swelling ratio of the NPs is optimized for specific pH and temperature 
conditions; also the degradation rate of the NPs can be controlled using a biodegradable 
cross-linker. [8,19,20] Furthermore, the PAA NPs can be modified with various drugs or 
dyes through three facile modification methods: a) pre-conjugation, b) encapsulation and 
c) post-loading or post-conjugation (Scheme 1-1). Due to their above advantages, the 
PAA NPs have been used for many purposes, for example, for intracellular calcium ion 
or oxygen chemical sensing, as chemo-drug delivery carriers for ovarian cancer and as 
hydrophobic photosensitizer delivery carriers for photodynamic therapy (PDT), and for 
tumor delineation applications. [10-14,21]   
 




Silica/ormosil NPs are the nanoplatform synthesized by organic functionalized silane, 
based on the sol-gel process. In contrast with traditional silica NPs, the ormosil NPs are 
synthesized in two steps: 1) hydrolysis of organic modified silane and 2) condensation of 
the silane. [22,23] The hydrophobic precursor, phenyhltrimethoxysilane (PTMS), is 
hydrolyzed under acidic conditions and then forms a 3-dimentional network for the NPs 
by condensation under basic conditions. [12,22] The size of ormosil NPs ranges from 300 
– 800 nm but this size could be adjusted by control of the hydrolysis time and the 
concentration of PTMS. After such adjustment, the size of ormosil NPs was 100 – 800 
nm, which is an appropriate size for use as an intracellular nanosensor. [23] The ormosil 
is hydrophobic, thus the NPs are poorly dispersed in aqueous media. Through surface 
modifications of ormosil NPs, coating with a relatively less hydrophobic precursor, 
methyltrimethyoxy silane (MTMS), helps to increase the suspension of ormosil NPs. 
Furthermore, using amine functionalized (3-aminopropyl)trimethoxysilane (APTMS), 
provides primary amines, which enables further modification with drugs, dyes or 
targeting moieties. [12] A subshell coating helps to load hydrophobic dyes inside the 
ormosil NPs without interference with the initial particle formation by adding the dye 
before the MTMS condensation. [23] In addition to hydrophobic dyes, hydrophilic dyes 
can be easily loaded into ormosil NPs by adding an initial acidic reaction mixture. 
Silica/ormosil NP is inert and biocompatible (but not biodegradable), thus this NP has 
been successfully used as nanocarrier to deliver a hydrophobic photosensitizer (PS) 
including, 2-(1-hexyloxyethyl)-2-devinyl pyropheophorbide-alpha (HPPH), meta-
tetra(hydroxyphenyl)chlorin (mTHPC) and Methylene Blue (MB), or the contrast agent, 




been used as a nanosensor platform for Photonic Explorers for Biomedical uses with 
Biologically Localized Embedding (PEBBLE) nanosensor platforms, for the highly 
selective sensing of ions, hydrogen peroxide or for real-time measurement of O2 in live 
cells. [23,27-29] 
Kopelman group has also researched extremely small sized polymer nanoplatforms, 
in addition to their work on 3-dimentionally cross-linked PAA and silica/ormosil NPs. 
Most drug delivery NPs are optimized for cancer therapy, but sometimes it is necessary 
to deliver the drug to a normal organ which has a much smaller penetration widow than 
cancer tissue. [30] Thus, a very small sized (≤ 10 nm) polymer nanoplatform can be more 
useful than conventional cross-linked sphere shape NPs to specific organ, such as heart. 
Among the biocompatible materials for polymer nanoplatform, polyethylene glycol (PEG) 
is one of the promising polymers for biomedical applications. [31] The FDA approved 
standard PEG compound is a non-ionic hydrophilic polymer with a structure of “HO–
(CH2–CH2–O)n–H” and was commercialized already 20 years ago. [32-34] PEG is 
frequently used in biomedical applications, especially as a drug delivery system, since it 
has low toxicity and helps to prevent biofouling, enhances plasma circulation time, 
reduces aggregation of drugs, proteins or NPs, and increases the solubility of 
hydrophobic drugs in the physiological medium. [32,34-36] Also, there are several 
functionalized and specially shaped PEG polymers, making possible further 
modifications, depending on the purpose/use. [37,38]  Such drug loaded PEG polymers 
have been used for chromic hepatitis C, febril neutropenia, acromegaly and several 




There are several other promising, frequently used, nanoplatforms studied in other 
groups for biomedical applications, such as gold NPs, natural polymers and single-walled 
carbon nanotubes (SWNTs). The gold NPs, which are nano-sized, sphere shapes of gold, 
are used as immunostaining, single particle tracking, contrast agents for X-rays or 
photoacoustic imaing, and as a photo-drug for photothermal therapy (PTT), through easy 
modification of its surface by conjugation with thiol group fucntionalized drugs or 
targeting moieties. [39,40] The natual polymers are mainly classified as 
protein/polypeptides (e.g. collagen, gelatin, albumin, polylysine, elastin-like polypepetide 
(ELP)) and polysaccharides. The polysaccharides are further categorized as anionic 
(alginate, hyaluroanan), cationic (chitosan) and neutral (pullulan, agarose, dextran, 
cellulose) polymers. [8] These natural polymers are inherently biodegradable under bio-
enzymatic conditions and have abundant functional groups (-OH, -NH2, and -COOH) for 
modification with drug, dye or targeting moieties towards drug delivery or other 
therapeutic purposes. The SWNTs are nano-sized SP2 hybridized carbon materials, 
frequenlty used as Raman and photoacoustic imaging contrast agent or as a delivery 
system for drugs, genes, and small molecules, due to its unique physical properties. 
[3,41,42] In addition to the above mentioned nanoplatforms, dendrimers, magnetic NPs, 
quauntum dots, and liposomes are frequenlty studied as carriers for biomedical imaging 
and therapeutic purposes. [3,4,43] 
1.2 Biomedical Optical Imaging with Nanoplatforms 
The lack of a suitable biomedical analyzing technique made it difficult to diagnose 
diseases appropriately. Detecting and diagnosing disease at an early stage is very critical 




imaging technology plays a very important role in accurate diagnosis using cellular and 
molecular level visualization. [4,5] There are several biomedical imaging modalities, 
such as magnetic resonance (MR), single photon emission computed tomography 
(SPECT), ultrasound (US), computed tomography (CT), positron emission tomography 
(PET), single photon emission computed tomography (SPECT) and optical imaging. [6] 
Among these, optical imaging technology has been the focus, due to its versatility, low 
cost, low hazard, and its high spatial resolution and sensitivity; examples include 
fluorescence, Raman and photoacoustic imaging, and optical coherence tomography 
(OCT). [4,5,44,45]  
Fluorescence imaging (FI) is one of the frequently used optical imaging modalities 
that enable both in vitro and in vivo level analysis for several diseases (e.g. hepatic 
excretory function, uterine blood flow, lymph nodes in breast cancer, atherosclerotic 
plaques, and retinal angiography). [46-52] The fluorescence imaging technique has the 
following advantages; 1) high signal to noise ratio (SNR); 2) simplicity, 3) high 
sensitivity, 4) ease of operation, 5) fast imaging speed, 6) capability to provide molecular 
level information, 7) low cost. [46] FI is based on the emission light of the image contrast 
agents, fluorophores. The ground state of the fluorophore is excited by absorbing light 
energy (photons) transition to an excited state (in femtoseconds) and then returns to the 
ground state by emitting fluorescence light (in nanoseconds). [53] This fluorescence 
emission is usually at a longer wavelength compared to absorption, so the exciting light 
can be filtered perfectly without interfering with the emission light. The fluorescence 
optical imaging technique has great sensitivity and selectivity for in vitro study but has 




attenuation. [5] As advanced techniques for in vivo fluorescence microscopy, several new 
microscope modalities are emerging, such as intravital confocal, two-photon, and multi-
photon microscopies, which enable better resolution and light penetration depth. [44]  
In company with fluorescence imaging, photoacoustic imaging (sometimes called 
optoacoustic or thermoacoustic imaging) is also a promising noninvasive optical imaging 
modality for human organs like breast or brain, due to its combination of light and 
ultrasound use advantages. [3,54-56] In the photoacoustic phenomenon, the acoustic 
waves are created by the instantaneous thermal-elastic expansion in the tissues because 
the absorbed light energy is converted into heat. [54,57,58] Due to the combination of 
light and ultrasound, the photoacoustic imaging modality has fine spatial resolution 
combined with good depth of imaging, because of the weak scattering of ultrasonic 
waves in living tissue. It also has high contrast in tissue, due to strongly optical absorbing 
contrast agents. [56] For the high penetration depth, longer optical waves, especially in 
the near-infrared (NIR) range (700 – 900 nm), are used in photoacoustic imaging, so as to 
avoid light absorption by hemoglobin in the blood (400 – 600 nm) and by water (≥ 900 
nm). [54,56,59] Thus, the contrast dye with high absorbance at a proper NIR frequency 
used, such as the Indocyanine Green (ICG) and Coomassie Blue, are usually used. [55,59] 
However, most of the image contrast agents have their own limitations, such as fast 
degradation, aggregation, toxicity and lack of targeting. [60,61] For enhanced sensitivity 
and selectivity of the optical imaging quality in vivo, as well as in vitro, nanotechnology 
has been applied to these optical imaging techniques. For instance, fluorescence dye 
doped functionalized silica NPs increase the sensitivity by amplifying the optical signal 




Quantum Dots which are fluorescence semiconductor nanocrystals have advantages over 
free dye due to higher quantum yield, higher chemical stability, and long fluorescence 
life time with narrow fluorescence emission spectra. [63-65] In addition, gold NPs and 
SWNTs are good contrast agents for photoacoustic imaging; also targeting moiety (RGD) 
loaded SWNT (SWNT‒RGD) increase the selectivity of the photoacoustic signal. [5,66]  
The multipurpose designed nanoplatform (multifunctional nanoplatform) allows for 
multimodal biomedical imaging by a combination of several imaging techniques. [6,67] 
Because of the heterogeneity of diseases and patient, one imaging technique provides 
limited information but a hybrid of several imaging modalities helps to make a more 
accurate diagnosis. [3,6] Furthermore, due to the advantages of carrying various imaging 
contrast agents and chemo-drugs simultaneously, the multifunctional nanoplatforms are 
also used for a theranostic (therapeutics + diagnostics) purpose, which enables both 
diagnosing and treating the disease at the same time. [3,4,68]   
1.3 Photodynamic Therapy (PDT) with Nanoplatforms 
The biomedical applications of nanoplatforms are not limited to diagnostics, but can 
be extended to the treatment of diseases.  Among the treatment methods, there have 
occurred in history a lot of efforts to apply the properties of light to therapeutic purposes 
dating back for thousands of years ago. [69] Ancient people in Egypt, China and India 
cured psoriasis, rickets and skin cancer and in the 19
th
 century, Finsen used red light and 
ultraviolet (UV) light to treat smallpox pustules and cutaneous tuberculosis. [69] 
Nowadays, PDT is an FDA approved therapeutic modality used to treat various localized 
diseases (cancer, cardiovascular, ophthalmic, dermatological and dental diseases) due to 




treatment, ability of repeated treatment at the same site, and suitability for patients too old 
or sick for conventional surgery. [24,70,71]   
PDT is achieved by the combination of three important components: photosensitizer, 
O2 and appropriate light source. [24,72] The photosensitizer is a light sensitive molecule 
that absorbs a specific wavelength of light and this absorbed light energy activates the 
photosensitizer. [69] Following absorption of the light (photon) energy, the 





 s). Then, the photosensitizer emits the photon as light energy returning to the 
ground state (fluorescence) or transforms to an excited triplet state, which has a much 
longer life time (10
-3
 – 10 s) through intersystem crossing. [73] Through two different 
pathways, the excited triplet state PS can produce several highly oxidative molecules and 
radicals called reactive oxygen species (ROS): (1) The excited triplet state PS reacts with 
substrates like cell membrane or other molecules to directly produce radicals or radical 
ions through electron and hydrogen transfer (Type I). (2) The excited triplet state PS 
transfers its energy to a ground triplet state O2 molecule, producing the highly reactive 
singlet oxygen (
1
O2) (type II) (Scheme 1-2). [24,69,74,75] These two different types of 
ROS production occur at the same time, and the ratio of type I and type II depends on the 
type of PS and the environmental condition, such as the concentration of O2 or substrate. 
Because of their high reactivity, ROS not only function as physiological regulators of 
intercellular signal pathways but are also cytotoxic, whereby they induce cell death, 
either by apoptosis or necrosis, through oxidation. [74,76-78] However, the PDT effect is 
very limited in range and localized to the PS loaded and/or light illuminated area. This is 




vivo is around 0.03 – 0.18 µs and the diffusion distance is 11 – 27 nm. [24,69] Similarly, 
in Type I PDT, the life time of the free radicals is also short (≤ 1 ms), as is their diffusion 
distance. [79] 
 
Scheme 1-2 Reaction kinetics of photosensitizaton leading to PDT (Types I and II). [24] 
 
There are several already developed and approved PSs (Table 1-1), which are 
designed based on the following factors: [69,73]  
1) Strong absorption in near infrared (NIR) range (600 – 850 nm) with a high 
extinction coefficient; 
2) High quantum yield of triplet formation to generate ROS; 
3) Negligible cytotoxicity in absence of light (low dark toxicity); 
4) Higher targetability in diseased area; 
5) Rapid clearance (excretion) from body after PDT, to avoid prolonged 
photosensitivity; 
6) Single and well characterized stable compound with high-yield synthetic route; 




Table 1-1 Type of cancer and approved drugs (2003). [69] 
Disease Drug Country 
Pre-cancer   
Actinic Keratosis Levulan, 
Metvix 
EU 
Barrett's oesophagus Photofrin EU, USA 
Cevical dysplasia Photofrin Japan 
Cancer   
Basal-cell Carcinoma Metvix EU 
Cervical cancer Photofrin Japan 
Endobroncheal cancer Photofrin Canada, Denmark, Finland, France, 
Germany, Ireland, Japan, The 
Netherlands, 
UK, USA 
Oesophageal cancer Photofrin Canada, Denmark, Finland, France, 
Ireland, Japan, The Netherlands, 
UK, USA 
Gastric cancer Photofrin Japan 




Photodynamic therapy has also been undertaken in other countries with haematoporphyrin 
derivative and porphtin mixtures (China and India), and phthalocyanines (Russia and India). EU, 
European Union; UK, United Kingom; USA, The United States. 
 
However, these PS do not perfectly satisfy all the above criteria. For example, the 
most common PS, Photofrin
®
, is not an ultimate PS due to its rapid photobleaching, long 
term skin phososensitivity, difficulty of chemical modification and being a mixture of 
dimers or oligomers. [73] Thus, there are many efforts to develop a new PS or to use a 
nanocarrier to better satisfy the above criteria, in the interest of increasing PDT efficacy 
and decreasing inherent limitations of PDT. Because of superiority of NP agents, there 
are already many PS mediated NPs, based on PAA, Poly (D,L-lactide-co-glycolide) 
(PLGA), ormosil, dendrimer and natural polymers for cancer. [24] The relatively 
hydrophilic nanocarriers, compared to hydrophobic PDT drugs, encapsulate the PS inside 




different organs and maximize efficiency of treatment, PDT drug loaded nanoplatforms 
are modified with a targeting moiety specific to a cancer cell line. [15,80] Also, the 
nanoplatform protects PDT drugs from bio-enzymes in the blood-stream and increases 
targeting efficiency by adding targeting peptides onto the NP surface. [80,81] These 
efficient PDT drug loaded nanoplatforms may eventually be applied to other diseases 
than cancer, such as heart arrhythmia. [82]  
1.4 Overview of Dissertation 
In this dissertation, engineering of nanoplatforms, PAA NPs and 8-armed PEG, is 
reported for optical imaging purposes and for use in PDT of cancer and cardiac 
arrhythmia diseases. For treating cancer, a correct diagnosis should, ideally, always 
precede the selection of appropriate treatment. Thus, we first focus our efforts to detect 
the disease by improved optical imaging contrast agents. In Chapter 2, it was attempted to 
prepare NPs which enable not only enhancement of the chemical stability of the contrast 
agent, based on the advantages of human serum albumin (HSA), but also on operating 
multifunctional imaging techniques. HSA conjugated PAA NPs were used to deliver a 
contrast agent, the FDA approved ICG, with enhanced thermal- and photo-stability. After 
optimizing the ICG loading, these NPs were tested for their photoacoustic signal intensity 
at varied wavelengths and modified with F3 targeting moieties to provide selective 
fluorescence intensity in different cancer cell lines.  
In the next step towards managing cancer, research on cancer treatment is carried out. 
Among the therapeutic methods, in Chapter 3, we focus on PDT as a therapeutic modality, 
so as to remove the tumor without traditional surgery. As a new photo-drug, MB 




dimethacrylate (PEGDMA, Mn = 550) in order to overcome previously reported 
limitations. [15] Furthermore, their ROS productivity was analyzed and qualified by 
utilizing two different dyes, anthracence-9,10-dipropionic acid (ADPA) and Singlet 
Oxygen Sensor Green (SOSG). With the help of a new microfluidic device, a new PDT 
efficacy test is introduced which is capable of simultaneous testing of several NP samples 
under identical conditions. 
In Chapter 4, we demonstrate a new approach of using PDT to treat cardiac 
arrhythmia. Up to date, cardiac arrhythmia is usually treated by anti-arrhythmic drugs, 
surgery and/or catheter ablation, methods which carry a high risk of surgical 
complications, unwanted cellular damage or serious drug side effects. [82] Thus, it was 
planned to selectively ablate only myocytes, the cells which cause arrhythmia, by using a 
targeted and photosensitizer embedded nanopatform. For an in vivo experiments, an 
extremely small sized nanoplatform, 8-armed polytheylene glycol (8-arm PEG) was 
conjugated with the photosensitizer Chlorin e6 (Ce6) and the cardiac targeting peptide 
(CTP) to provide new nanoplatform (CTP‒Ce6‒PEG) due to the limited size of the 
cardiac capillary vessels’ fenestrations (pores), which is much smaller than for cancer. 
The new photo-drug, CTP‒Ce6‒PEG, was used to demonstrate selective myocyte killing 
by in vitro PDT as well as to explore in vivo targeting ability leading to selective cardiac 
ablation for arrhythmia using PDT ablation in the live heart of a rat.  
Lastly, in Chapter 5, a summary of the thesis is given with a discussion of future 
directions for each project, including 1) in vivo toxicity test on the nanoplatform, 2) 
theranostic modification of the nanoplatform, and 3) a new type of photosensitizer‒
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POLYMER-PROTEIN HYDROGEL NANOMATRIX FOR STABILIZATION OF 
INDOCYANINE GREEN TOWARDS TARGETED FLUORESCENCE AND 
PHOTOACOUSTIC BIO-IMAGING 
The contents in this chapter have been adapted with minor modifications from the 
following publications: 
Yoon, H.K.; Ray, A.; Koo Lee, Y.-E.; Kim, G; Wang, X.; Kopelman, R. J. Mater. Chem. 
B 2013, 1, 5611-5619. 
2.1 Introduction 
Indocyanine Green (ICG) is a Food and Drug Administration (FDA) approved 
tricarbocyanine fluorescent dye; it is negatively charged and is extremely water soluble. 
[1-5] It has absorption and fluorescence maxima in the near-infrared (NIR) region, 
around 780 nm and 820 nm, respectively. [6-8] The use of NIR radiation facilitates deep 
tissue imaging in vivo, due to good penetration of the NIR photons. Moreover, biological 
tissues have significantly reduced autofluorescence in the NIR region, which also leads to 
a much better signal to noise ratio (SNR) as compared to visible radiation. [1,5]  
ICG has been used as a contrast agent for fluorescence imaging (FI), which is one of 
the most commonly used medical imaging modalities, and is also a good contrast agent 
for the photoacoustic imaging (PI). [9-11]. Although ICG is one of the most widely used 
contrast agents for FI and PI, its applications have often been limited due to its intrinsic 
drawbacks, such as: 1)  it does not have specificity towards the target tissue; 2) it 
aggregates to form dimers and oligomers, depending on the local dye concentration 
(dimers and oligomers at concentrations > 3.9 mg∙L
-1








), leading to a reduction in signal intensity; 3) the “naked” dye gets degraded 
under enzymatic in vivo conditions, by losing its carbon-carbon double bond in its 
conjugated chain, which results in the formation of a colorless leuko form; 4) in the blood 
circulatory system, ICG has a short circulation lifetime (t1/2 = 2 - 4 min), as it is rapidly 
bioeliminated through the kidneys; and 5) ICG shows lower fluorescence intensity with 
increasing temperature, making it more difficult to obtain strong signals under in vivo 
conditions, compared to room temperature. [1,2,5,12-15] 
 Recently, diverse approaches have been utilized to overcome the above 
mentioned disadvantages of ICG as an imaging contrast agent. Metallic particles such as 
gold and silver colloids have been used to enhance the fluorescence and photo-stability of 
ICG, utilizing the metal enhanced fluorescence (MEF) effect, which occurs due to the 
presence of surface plasmons on the noble metal surface. [7,16] It was also reported that 
biocompatible nanocarriers such as phospholipid–polyethylene glycol (PL–PEG), 
poly(lactic–co–glycolic acid) (PLGA) and organic modified silica (Ormosil) 
nanostructures have been utilized for the purpose of increasing the thermal- and photo-
stability of ICG in aqueous solutions. [12,14,17-19] In addition, specific targeting of ICG 
was accomplished by attaching targeting moieties  to the surface of  a carbon nanotube, 
acting as a nanocarrier, to increase the cellular uptake and obtain stronger contrast 
enhancement. [10,20]  
 Here, a new kind of polymer/protein hybrid nanoparticle – a polyacrylamide 
nanoparticle (PAA NP) incorporated with human serum albumin (HSA), decorated with 
tumor-specific peptide on the surface – was developed as a tumor-targeting nanocarrier of 




has a high affinity towards ICG through non-covalent bonding, resulting from 
electrostatic interactions, hydrophobic interactions and hydrogen bonding. [21-23] The 
PAA NPs have been shown to be promising nanoplatforms for in vivo applications, such 
as sensing and drug delivery, for both diagnosis and therapy, due to their excellent 
biomedical properties and engineerability, including high aqueous solubility, small size, 
nontoxicity, biodegradability and easy surface modification with PEG, for longer 
circulation times, as well as with targeting moieties, for high targeting efficiency. [24-29] 
In addition, the PAA nanomatrix efficiently protects the encapsulated chromophore from 
external interference. [30,31] Due to these advantages, it has already been shown that 
loading of PAA NPs that include ICG into brain tumor cells can be used for tumor 
delineation purposes. [32]  
 We incorporated HSA into the PAA NPs so as to help overcome the drawbacks of 
free ICG dye molecule, while maximizing biocompatibility by keeping all the in vivo 
advantages of the PAA nanoparticles listed above. We report on 1) the optimized loading 
parameters of ICG into HSA–PAA NPs, 2) minimizing perturbations on the chemical and 
physical properties of ICG (i.e. reduced chemical degradation, and increased thermal- or 
photo-stability), 3) the use of ICG–HSA–PAA NPs for photoacoustic response, and 4) the 
specific targeting capabilities of the NPs towards tumoric endothelial cells through 







2.2 Experimental Section 
 Materials 2.2.1
Materials. Indocyanine Green (ICG), acrylamide (AA), acrylic acid N-
hydroxysuccinimide ester (NAS) (≥ 90%), glycerol dimeathacrylate, mixture of isomers 
(85%) (GDMA), ammonium persulfate (APS), N,N,N’,N’- tetramethylethylenediamine 
(TEMED), sodium dioctylsulfosuccinate (AOT), Brij 30, dimethyl sulfoxide (DMSO), L-
cysteine, and 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT agent), 
Phosphate buffered saline (BioReagent, pH 7.4, for molecular biology), fluorescein 5(6)-
isothiocyanate (FITC), and hexane were purchased from Sigma-Aldrich. N-(3-
aminopropyl)methacrylamide hydrochloride (APMA) was purchased from Polysciences. 
Coomassie protein assay kit and 8-well chambered cover glasses were purchased from 
Thermo Scientific. Ethanol (95%) was purchased from Fisher Scientific. F3–Cys peptide 
(KDEPQRRSARLSAKPAPPKPEPKPKKAPAKKC) was purchased from SynBioSci. 
The heterobifunctional polyethylene glycol (MAL–PEG–NHS, 2 k) was purchased from 
Creative PEG Works. Six-well cell culture plates and 96-well microplates were 
purchased from BD Biosciences. Roswell Park Memorial Institute 1640 medium (RPMI), 
RPMI 1640 medium, no Phenol Red (colorless RPMI) and Dulbecco’s phosphate 
buffered saline (DPBS) were purchased form Life Technologies. The water was purified 
with a Milli-Q system from Millipore. All chemicals were used without further 
purification. 
 ICG loaded Nanoparticle Synthesis 2.2.2
Preparation of HSA–PAA NPs. The HSA–PAA NPs were prepared by reverse 




synthesis. [25] The monomer solution was prepared in two steps: 1) dissolving HSA (67 
mg) in 1 mL of PBS (pH 7.4) and then adding 0.3 mL of NAS (1.7 mg) to the HSA 
solution under stirring for 2 h at 37 °C; 2) adding AA (689.5 mg), APMA (53.6 mg) and 
then subsequently GDMA (85%, 360 µL), a cross-linker, to the mixture solution under 
stirring. This monomer solution was added to 45 mL of deoxygenated hexane that 
contained surfactants, AOT (1.6 g) and 3.3 mL of Brij 30 (3.1 g). After stirring the 
mixture under inert atmosphere for 20 min, 100 µL of TEMED and a freshly prepared 
100 µL of APS (10%, w/v) were added to the mixture solution to initiate polymerization. 
The reaction mixture was stirred under inert atmosphere at room temperature. During the 
radical polymerization, the double bonds in monomer and cross-linker react with initiator 
or initiated monomers, resulting in a three dimensional polymer network. After 2 h, the 
solution was concentrated by rotary evaporator and the remaining residue subsequently 
suspended in ethanol. The reaction mixture solution was transferred into an Amicon 
Stirred Ultrafiltration Cells (200 mL, equipped with a Biomax 300,000 MWCO 
membrane) and washed thoroughly with ethanol and distilled water five times 
respectively. After washing and freeze-drying, 1.0 g (94%) of HSA–PAA NPs was 
obtained (Scheme 2-1). 
Preparation of ICG–HSA–PAA NPs. ICG stock solution (1 mg∙mL
-1
) was prepared 
in purified water.  HSA–PAA NP (50 mg) was dissolved in 8.5 mL of pure water and 
stirred for 1 h at room temperature. 1.5 mL of ICG stock solution (1 mg∙mL
-1
 in pure 
water) was added into nanoparticle solution and stirred during 2 h at room temperature. 




centrifugal cell (100 kDa). After washing, the NPs were freeze-dried and 42.7 mg of 
ICG–HSA–PAA NPs were obtained. 
Preparation of F3–ICG–HSA–PAA NPs. HSA–PAA NPs (50 mg) were dissolved 
in 8.5 mL of PBS (pH 7.4) and stirred and sonicated until the solution became 
homogeneous. 4 mg of bi-functional PEG (MAL–PEG–SCM, 2k) was added into 
nanoparticle solution and stirred at room temperature. After 20 min, 1.5 mL of ICG 
solution (1 mg∙mL
-1
 in water) was added and stirred for another 10 min. The NPs solution 
was washed three times with PBS (pH 7.4) by Amicon centrifugal filter (100 kDa).  After 
diluting the solution into a 5 mg∙mL
-1
 solution in PBS (pH 7.4), 7mg of F3–Cys peptide 
was added and the solution was stirred for 2 h at room temperature. To inactivate 
unreacted maleimide esters, 1.74 mg of L-cysteine was added to the solution and stirred 
for another 1 h. F3–(3% ICG)–HSA–PAA NPs were washed completely with water using 
Amicon centrifugal filter (100 kDa). After freeze-drying, 33.0 mg of F3–ICG–HSA–PAA 
NPs were obtained (Scheme 2-1). 
 





Dynamic Light Scattering Measurement. The size and surface charge of the NPs 
were measured using dynamic light scattering (DLS) with a Delsa Nano C particle 
analyser (Beckman Coulter). For the size measurements, the HSA–PAA NPs solution 
was prepared in PBS (pH 7.4) (0.5 mg∙mL
-1
), stirred for 1 h and sonicated for 5 min. For 
the surface charge measurements, the sample solution was prepared in pure water instead 
of PBS (pH 7.4). All the measurements were conducted in triplicate. 
Absorbance & Fluorescence Measurement. To monitor the ICG–HSA–PAA NPs’ 
absorption spectrum, UV-1601 UV-vis spectrometer (Shimadzu) was used. A 
FluoroMax-3 Spectrofluorometer (Jobin Yvon Horiba) was used for fluorescence 
measurements. The ICG–HSA–PAA NPs solution was prepared (0.1 mg∙mL
-1
) in PBS 
(pH 7.4). The measurements were conducted in triplicate. 
Temperature dependent Fluorescence Test. Fluorescence spectra of 2 mL of (3% 
ICG)–HSA–PAA NPs, (3% ICG)–PAA NPs (0.1 mg∙mL
-1
), and of naked ICG (0.00291 
mg∙mL
-1
) in PBS (pH 7.4), were measured at 25 °C. The temperature was then increased 
to 37 °C, in a temperature control chamber, and each sample was incubated for 5 min in 
the chamber. Any molecular degradation that might have occurred during this incubation 
period has been corrected, based on Figure 2-4a. All measurements were conducted in 
triplicate. 
Photo-stability Test. 3 mL of (3% ICG)–HSA–PAA NPs, (3% ICG)–PAA NPs (0.1 
mg∙mL
-1
), and naked ICG (0.00291 mg∙mL
-1
) in PBS (pH 7.4) were placed at 9 cm below 




were exposed to UV light for 10 min at room temperature. The fluorescence spectra were 
obtained before and after the light exposure and compared. 
Transmission Electron Microscopy (TEM). The TEM image was obtained using a 
Philips CM-100 transmission electron microscope. The NP sample for TEM was 
prepared by dissolving 0.1 mg of (3% ICG)–HSA–PAA NPs in 1 mL of pure water. The 
NPs were stained with uranyl-acetate and imaged on carbon coated copper grids.  
Coomassie Protein Assay. The amount of HSA in HSA–PAA NPs was analyzed by 
Coomassie protein assay. 30 µL of HSA–PAA NPs solution (10 mg∙mL
-1
 in PBS (pH 
7.4)) was added into 1.5 mL of Coomassie protein assay solution. As a control sample, 30 
µL of pure PBS (pH 7.4) was mixed with 1.5 mL of Coomassie protein assay solution. 
The absorbance of this mixture and that of the control were taken at 595 nm and the HSA 
amount was calculated from a calibration curve made with free HSA. 
Photoacoustic Set-up and Measurement. A homemade photoacoustic imaging 
setup (Scheme 2-2) was employed to obtain the photoacoustic spectra from the ICG 
loaded NPs. A tuneable optical parametric oscillator (OPO) (Vibrant B, Opotek) pumped 
by the second harmonic of a Nd:YAG laser (Brilliant B, BigSky), with a pulse duration 
of 10 ns, a tuning range of 700 - 800 nm, and a repetition rate of 10 Hz was used as the 
excitation source. This light was collimated and used to illuminate a transparent soft 
tubing (0.58 mm - BD Intramedic), mimicking a blood vessel, containing the ICG NPs. 
The NPs were used at a concentration of 5 mg∙mL
-1
. The OPO was used to illuminate 
ICG–HSA–PAA NPs flowing through soft tubing that mimics blood vessels. The light 
fluence was about 5 mJ∙cm
-2
, which is much lower than the ANSI standard limit of 30 
mJ∙cm
-2




of 9.01 MHz) ultrasonic transducer, cylindrically focused with a focal length of 0.75 inch, 
was used to detect the photoacoustic signals emitted by the NPs. The photoacoustic 
signals received by the transducer were amplified and digitized using a 500 MHz digital 
oscilloscope (TDS, 540B, Tektronix), and subsequently transferred to a computer. Each 
data point was obtained by averaging of 30 signal measurements. A beam splitter was 
used to direct a small fraction of the beam from the OPO to a photodiode (Model 2031, 
Newport Corporation) for the monitoring of laser fluctuation. This served to normalize 
the measured photoacoustic signal intensities so as to take into account any errors due to 
the instability in the laser output power. 
 
Scheme 2-2 Homemade setup for photoacoustic image. 
 
 In Vitro Tests 2.2.4
Cell Culture. Two different cell lines, rat gliosarcoma cell line (9L) and human 




heat inactivated fetal bovine serum (HI-FBS) and 1% Antibiotic-Antimycotic (100X). 
These cells were plated into 96 well plates for the cell viability assays and 8 well 
chambered slides for fluorescence imaging.  
Cytotoxicity (CCK-8 Assay). The cytotoxicity of the NPs was tested by the CCK-8 
assay, which is based on the reduction of tetrazolium salt, WST-8, to a water soluble 
formazan dye by the dehydrogenase activity of viable cells. [33] Approximately 5000 9L 
cells, in 100 µL of RPMI, were seeded on each well of a 96 well plate. The 25 µL of (3% 
ICG)–HSA–PAA NPs, HSA–PAA NPs and PAA NPs solution (10, 5, 2.5 and 1.25 
mg∙mL
-1
 in PBS (pH 7.4)) were added into each well to prepare final NP concentrations 
of 2, 1, 0.5 and 0.25 mg∙mL
-1
. Wells containing 9L cells without any NPs treatment 
served as the control. After 24 h incubation at 37 °C, the NP solutions were removed 
gently to avoid absorbance interference of ICG and/or phenol red with WST-8 formazan 
dye. CCK-8 stock solution (9% (v/v) CCK-8 in colorlesss RPMI, no phenol red) was then 
pipetted into each well (100 µL) and incubated for 4 h at 37°C. The amount of WST-8 
formazan dye produced was analysed, by measuring absorbance at 492 nm, by an Anthos 
2010 Microplate Absorbance Reader (Biochrom Ltd.). 
Fluorescence Imaging. For fluorescence imaging, both 9L (F3 positive cell line) and 
MCF-7 cells (F3 negative cell line) were seeded into 8 well chambered slides. F3–(3% 
ICG)–FITC–HSA–PAA NPs, F3–(3% ICG)–FITC–PAA NPs and PEG–(3% ICG)– 
FITC–PAA NPs were added to each well to prepare a final concentration of 1 mg∙mL
-1
 in 
cell culture medium. After 30 min incubation, any unbound NPs were washed with DPBS 
three times, followed by addition of colorless RPMI. Confocal fluorescence images were 




2.3 Results and Discussion 
 Characterization of ICG–HSA–PAA NPs 2.3.1
Compared to traditional PAA NPs, the HSA–PAA NPs have a larger size, presumably 
due to the inclusion of HSA inside the NPs. The hydrodynamic size of PAA NPs was 
63.3 (± 1.0) nm and the zeta potential was 25.2 (± 0.9) mV, as measured by DLS. For the 
HSA–PAA NPs, the size increased to 136.6 (± 15.4) nm, but the zeta potential was 26.1 
(± 0.7) mV, similar to that of the PAA NPs. The negative charge of the HSA did not 
affect the overall surface charge, probably since most of the conjugated HSA were 
present inside the polymer matrix. After ICG post-loading, neither size nor zeta potential 
of the NPs changed much. The latter were recorded, respectively, as 67.3 (± 2.1) nm and 
24.9 (± 0.5) mV for (3% ICG)–PAA NPs and as 133.1 (± 7.2) nm and 24.5 (± 0.7) mV 
for (3% ICG)–HSA–PAA NPs (Table 2-1). In addition to the hydrodynamic NPs size, we 
also monitored the dehydrated size of the NPs using TEM. The size of the dehydrated (3% 
ICG)–HSA–PAA NPs was around 48 nm (Figure 2-1). We note that the hydrogel matrix 
easily swells under aqueous conditions but shrinks back when it is dried, leading to a 
difference between the actual volume and the hydrodynamic volume. [25] The amount of 
HSA in the NPs was determined by a Coomassie protein assay kit and 403.3 µg of HSA 
was incorporated in 10 mg of HSA–PAA NPs, which amounted to 4% (w/w) of loading 
in NPs. To achieve specific targeting, the NPs were attached to the F3 peptide by using a 
bi-functional PEG as cross-linker, which was conjugated to the primary amines in APMA 
prior to ICG loading. This order was chosen since if ICG is loaded in advance, the 












Zeta Potential (mV) 
PAA NPs 63.3 (± 1.0) 25.2 (± 0.9) 
(3% ICG)–PAA NPs 67.3 (± 2.1) 24.9 (± 0.5) 
HSA–PAA NPs 136.6 (± 15.4) 26.1 (± 0.7) 
(3% ICG)–HSA–PAA NPs 133.1 (± 7.2) 24.5 (± 0.7) 
 
 
Figure 2-1 TEM image of (3% ICG)–HSA–PAA NPs. 
 
 Optimization of ICG Loading within HSA–PAA NPs 2.3.2
ICG has a tendency to aggregate and also leach out of the NP platform when it is 
loaded at high concentrations. To optimize the ICG loading into the NPs, different 
amounts of free ICG were loaded into HSA–PAA NPs. During the radical polymerization, 
ICG loses its double bond and is converted into a leuko form, preventing it from being 
preconjugated or encapsulated in the nanomatrix. Thus HSA–PAA NPs were loaded with 
ICG by the post-loading method, which is a quick and easy modification method which 




(w/w), ICG was loaded into the HSA–PAA NPs through post-loading modification that is 
free of any dye leaching. 
 We monitored the absorption spectra from the HSA–PAA NPs containing 
different amounts of ICG (Figure 2-2a).  At lower ICG loading, we observe a strong 
absorbance around 780 nm which corresponds to the free ICG monomer. However, on 
increasing the amount of ICG, there was a marked increase in the absorbance at 720 nm, 
due to the formation of ICG dimers. We also compared the fluorescence from the ICG–
HSA–PAA NPs’ for different ICG loadings (Figure 2-2b). Since the (3% ICG)–HSA–
PAA NPs have the highest fluorescence signal, we used the 3% loading for all further 
experiments.  
 
Figure 2-2 (a) Absorption spectra and (b) normalized fluorescence emission spectra of 
ICG–HSA–PAA NPs, using 780 nm excitation. The absorption and fluorescence 
measurements were taken with 0.1 mg∙mL
-1
 of 0.5 - 12% (w/w) ICG loaded HSA–PAA 
NPs in PBS (pH 7.4) buffer, showing spectral changes with different ICG loading. 
 
 In Vitro Test Results for Toxicity 2.3.3
Polyacrylamide hydrogel is a nontoxic polymer and has been used extensively in 
biomedical applications. [29,34] The nontoxicity of PAA NPs was demonstrated in 




PAA NPs are expected to be non-toxic since HSA is one of the constituents of human 
blood and ICG is already an FDA approved dye. To test the NP’s toxicity, we performed 
a cytotoxicity assay using a CCK-8 assay on the 9L cell line, with a variety of NPs 
concentration (0.25, 0.5, 1 and 2 mg∙mL
-1
). All (3% ICG)–HSA–PAA, HSA‒PAA and 
PAA NPs showed higher than 98% cell survival over the 24 h incubation time (Figure 2-
3). This result demonstrates that the ingredients of ICG–HSA–PAA NPs do not cause any 
cytotoxicity. 
 
Figure 2-3 Cytotoxicity of NPs in 9L cells. Cell viability of (3% ICG)–HSA–PAA, 
HSA‒PAA and PAA NPs at various concentrations (0.25, 0.5 1, 2 mg∙mL
-1
) was 
monitored after 24 h incubation with NPs by CCK-8 assay (n =8). Control (100%) was 
9L cells incubated for 24 h without NPs. 
 
 Stability Enhancement of Post-loaded ICG within HSA–PAA NPs 2.3.4
The ICG–HSA–PAA NPs were designed to further enhance the chemical stability of 
ICG over ICG–PAA NPs. The PAA NPs, like other nano carriers, such as silica, PL–PEG 
and PLGA NPs, help to increase chemical stability of the ICG dye since the dye is 
trapped inside the porous PAA nanomatrix, thus limiting accessibility of other chemicals, 




hydrophobic cavities, binds strongly to the ICG molecules, thus offering greater stability 
to the ICG, compared to the HSA-less PAA NPs. [36,37] 
 First, encapsulation in the HSA–PAA NPs helps to improve the stability of ICG in 
aqueous solution. The degradation rate of free ICG and ICG in different matrixes in PBS 
(pH 7.4) were monitored by measuring the absorbance of ICG at different time points. 
The free ICG solution showed fast degradation and only 30 (± 3.9) % of the dye 
remained intact after 24 h at normal body temperature, 37 °C. However, 59 (± 6.4) % and 
69 (± 7.3) % of the ICG remained intact when encapsulated inside the PAA and HSA–
PAA NPs, respectively, over the 24 h period, at 37 °C (Figure 2-4a).  
Secondly, the HSA–PAA NPs also help to prevent the reduction of ICG fluorescence 
intensity due to rise in temperature, from 25 °C to 37 °C. For free ICG, we observed a 31% 
decrease in fluorescence intensity when the temperature was increased to 37 °C. The 
reduction in fluorescence can be attributed to faster diffusion of ICG at higher 
temperature, leading to an increased rate of collision with oxygen molecules, and thus 
increased quenching. [15] However, the reduction in fluorescence intensity was only 7% 
and 2% for ICG in PAA NPs and HSA–PAA NPs, respectively (Figure 2-4b), due to the 
limited mobility in the matrix. 
Lastly, the HSA–PAA NPs improve the photo-stability by preventing photo-
degradation of the ICG dye. Photo-degradation is an irreversible process that leads to a 
loss in optical properties due to the breakdown of dye molecule into smaller fragments 
through oxidation processes. [38] The photo-degradation renders the dye ineffective as a 
contrast agent, due to loss of colour, and also increases its photo-toxicity since ICG 




reduction in the photo-degradation of the ICG dye in the (3% ICG)–HSA–PAA NPs, 
compared to the free dye. After 10 min UV lamp exposure at 254 nm, 87% and 73% of 
ICG remained intact in the HSA–PAA and PAA NPs, respectively, while only 44% of the 
free ICG remained intact (Figure 2-4c). It is well known that this photo-decomposition is 
caused by reaction of photo-excited ICG molecules with solvent radical species and ions. 
[2] This protection from photo-decomposition by the NP platform could be attributed to 
the higher scattering cross section in the UV region of the spectrum and also limiting the 
interaction of the solvent radical species with the dye molecules compare to free ICG. 
Additionally, the hydrophobic pocket in HSA might prevent the interaction of radical 
ions and helps to further improve the photo-stability of ICG. 
 
Figure 2-4 Advantages of dye encapsulation in HSA–PAA NPs and PAA NPs. (a) 
Enhancement of ICG stability, under aqueous conditions at 37 °C, by PAA or HSA–PAA 
NPs; (b) Prevention of ICG fluorescence quenching, under physiological condition 
(37 °C) compared to room temperature (25 °C), by encapsulation in PAA or HSA–PAA 
NPs;  (C) Enhancement of ICG photo-stability, under UV lamp illumination (240 nm) for 
10 min, by encapsulation in PAA or HSA–PAA NPs. 
 
 Photoacoustic Response of ICG–HSA–PAA NPs 2.3.5
To demonstrate the feasibility of photoacoustic imaging using the NPs, we monitor 
the photoacoustic spectrum from ICG–HSA–PAA NPs (Scheme 2-2). The photoacoustic 




peaks at around 720 nm and 790 nm, which respectively correspond to the signals from 
the dimer and monomer forms of ICG. Interestingly, the signal peak corresponding to the 
dimer ICG is much stronger, as compared to the other peak corresponding to the 
monomer ICG. This is in contrast to the observed optical absorption spectrum of the NPs 
(Figure 2-2a), where the monomer peak showed a higher value than the dimer peak, at 3% 
loading, since the photoacoustic signal is generally proportional to the absorbance. This 
may be attributed to the higher fluorescence quantum yield for the ICG monomer, 
compared to its dimer form. For the ICG monomer, most of the energy is converted to 
fluorescence; whereas for the dimer form, most of the energy is converted to heat and 
subsequently to photoacoustic signal, due to the low fluorescence quantum yield. Thus 
we observed a higher photoacoustic signal at 720 nm than at 790 nm. 
 
Figure 2-5 Photoacoustic spectrum of (3% ICG)–HSA–PAA NPs (5 mg∙mL
-1
) in PBS 
(pH 7.4). 
 
 In Vitro Cell Targeting Using Fluorescence Imaging 2.3.6
The fluorescence imaging of ICG–HSA–PAA NPs and ICG–PAA NPs, both in 




using a Leica SP5X confocal microscope. Due to limited availability of appropriate light 
source and filters, we could not obtain clear ICG images. To overcome this limitation, we 
introduced FITC dye into the HSA–PAA NPs. FITC has a high fluorescence quantum 
yield and helped compliment the fluorescence signal from ICG, so as to determine the 
targeting efficiency, with very high accuracy, for each of the three NPs carrying ICG. To 
avoid leaching out, the FITC dye was pre-conjugated into the HSA–PAA and PAA NPs 
during NP synthesis, using a previously reported protocol, and then the ICG dye was 
post-loaded after conjugation of the targeting moiety, F3. [25] The F3 peptide was used 
since it is a commercially available targeting moiety and has been reported to bind to the 
nucleolin receptors, which are overexpressed in some cancer cells. [40,41] To study the 
specific binding ability of the ICG carrier, three different NPs were prepared, including 
F3–(3% ICG)–FITC–HSA–PAA NPs, F3–(3% ICG)–FITC–PAA NPs and PEG–(3% 
ICG)–FITC–PAA NPs. All three types of NPs were loaded into 9L and MCF-7 cell lines 
and incubated for 30 min, at a 1 mg∙mL
-1
 concentration. The 9L cells (high expression of 
nucleolin receptors) were used as a positive control, and the MCF-7 cells (lower 
expression of nucleolin) as the negative control. The targeting efficiency of the NPs was 
calculated, based on the fluorescence intensity from the cells. We observed a 2.4 and 2.3 
times higher binding efficiency in the 9L cell line, for F3–(3% ICG)–HSA–PAA NPs and 
F3–(3% ICG)–PAA NPs, respectively, compared to the MCF-7 cells (Figure 2-6). The 






Figure 2-6 Confocal images of F3 targeted selective delivery of ICG: A-a) F3–(3% 
ICG)–FITC–HSA–PAA NPs in 9L cells; A-b) F3–(3% ICG)–FITC–PAA NPs in 9L cells; 
A-c) PEG–(3% ICG)–FITC–PAA NPs in 9L cells; A-d) F3–(3% ICG)–FITC–HSA–PAA 
NPs in MCF-7 cells; A-e) F3–(3% ICG)–FITC–PAA NPs in MCF-7 cells; A-f) PEG–(3% 
ICG)–FITC–PAA NPs in MCF-7 cells; B) Relative cell specificity of F3 and ICG 
containing  NPs, based on averaged fluorescence intensity of the FITC fluorescence 
confocal image (blue bar is for 9L and red bar is for MCF-7 cells). For quantification, the 





In summary, a novel ICG nanocarrier based on a hybrid polyacrylamide matrix and 
HSA was developed, so as to effectively overcome the inherent drawbacks associated 
with the free ICG dye. This new type of NP carrier contains 40.3 µg of HSA per 1 mg of 
NPs, i.e. 4% (w/w) loading, with a size of 133.1 nm and surface charge of 24.5 mV. In 
vitro toxicity of the NPs was monitored at several concentrations, showing no significant 
biological toxicity. These NPs were modified by adding the contrast agent, ICG, and also 
the tumor targeting F3 peptides. The optimized ICG loading into NPs was found to be 3%, 
since at this loading, the NPs containing ICG have the strongest fluorescence intensity. 
The ICG–HSA–PAA NPs show an outstanding ability to protect the encapsulated ICG 
from 1) fast chemical degradation under aqueous conditions, 2) reduction in fluorescence 
at higher temperature, and 3) photo-degradation. The photoacoustic spectrum of ICG–
HSA–PAA NPs showed two strong peaks, at 720 nm and 790 nm, in the NIR range. 
However, contrary to the absorbance and fluorescence spectra, the dimeric ICG form 
(720 nm) shows a stronger photoacoustic signal than the monomeric form of ICG (790 
nm), due to the lower fluorescence quantum yield of the dimeric ICG form. Moreover, 
after successful modification with the targeting moiety, F3–Cys, these NPs showed high 
cell specific selectivity. We believe that this polymeric nanoparticle design could also be 
used as an efficient, biodegradable and biocompatible carrier for other kinds of 
fluorescent molecules, which could be of interest in important biomedical applications of 
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NANOPHOTOSENSITIZERS ENGINEERED TO GENERATE A TUNABLE 
MIX OF REACTIVE OXYGEN SPECIES, FOR OPTIMIZING 
PHOTODYNAMIC THERAPY, USING A MICROFLUIDIC DEVICE 
The contents in this chapter have been adapted with minor modifications from the 
following publication: 
Yoon, H.K.; Xia, L.; Chen, Yu-Chi; Koo-Lee ,Y.-E.; Yoon, E.; Kopelman, R. Chem. 
Mater. 2014, 26, 1592-2600. 
3.1 Introduction 
The reactive oxygen species (ROS) are several highly oxidative molecules and 
radicals such as singlet oxygen (
1
O2), hydroxyl radical, superoxide anion radical, 
hydrogen peroxide, etc. [1] These ROS can be generated by visible light with the help of 
appropriate photosensitizers. [1-3] This mechanism underlies photodynamic therapy 
(PDT), which is a clinically approved noninvasive localized therapeutic modality for 
cancer, cardiovascular, ophthalmic, dermatological and dental diseases. [3-9] The interest 
in optimizing nanophotosensitizers is associated with their advantages as PDT agents, 
due to their potential for increased efficiency, targetability and biocompatibility, as well 
as their theranostic (therapy + diagnostics) operation. [1.10-12]  
The utility of PDT in medical applications is restricted due to the following factors: 1) 
wavelength-dependent tissue penetration depth of the light, 2) inefficient delivery of 
photosensitizer (PS) to targeted area, 3) loss of PDT efficacy due to aggregation, 
degradation, or reduction of photosensitizers, and 4) dark toxicity of the photosensitizer. 




are applied as PS carriers, as the use of NPs can help overcome the limitations 2), 3) and 
4) listed above. [1,5,14-17] Methylene Blue (MB) is a promising PDT dye due to its high 
quantum yield (ФΔ ≈ 0.5) and long absorption wavelength (λmax = 664 nm), enabling a 
better light penetration depth in live tissue, as well as due to its high solubility in aqueous 
media. [10,18] However, MB’s use for in vivo PDT has been limited because of its 
conversion into an inactive form (leuko MB) by enzyme reduction reactions that occur in 
the blood stream. At higher concentration, MB may form aggregates that reduce the 
fluorescence quantum yield; furthermore, the MB molecule lacks specificity towards 
target tissues. [18,19] 
In our previous studies, MB loaded polyacrylamide nanoparticles (PAA NPs) have 
been developed by two different loading methods, encapsulation and chemical 
conjugation. [10,20] The PAA NPs were found to be biocompatible and biodegradable 
nanocarriers; moreover, the NP matrix was easily modified with targeting moieties and 
successfully protected the MB from reduction/conversion by bio-enzymes. [19,21-24] 
For making the MB NPs, the conjugation approach was found to be the most efficient 
method, demonstrated by higher loading, negligible leaching of MB from the nanocarrier, 
and by better PDT efficacy, probably due to a more homogeneous distribution of the high 
amounts of conjugated MB inside the NP matrix. [10] These MB conjugated PAA NPs 
showed a PDT efficacy (per 1 mg of NPs) of almost 9 times that of MB encapsulated 
PAA NPs. This PDT efficacy was estimated by the traditional kinetics-based method: i.e., 
by determining the rate constant, k, of the first order decay kinetics of anthracence-9,10-




Notably, upon increasing the photosensitizer loading, the MB conjugated PAA NPs 
showed an upper limit for the k value. The k value initially increased with MB loading, 
but then peaked and decreased. [10,21] This limitation on the PDT efficacy of the MB 
conjugated NPs — probably due to aggregation of MB moieties and self-quenching of 
produced excitations and/or ROS inside the nanocarriers — may be overcome by 
modifying the NP matrix structure through the use of longer cross-linkers. This is 
expected to allow 1) longer distances (gaps) between the conjugated MB moieties, 2) a 
higher oxygen permeability, and 3) a lower collision probability between the produced 
ROS. 
Herein, we present the preparation of a modified MB–PAA NP, which uses 
poly(ethylene glycol) dimethacrylate (PEGDMA, Mn = 550), a cross-linker that is longer 
than the 3-(Acryloyloxy)-2-hydroxypropyl methacrylate, (AHM, MW = 214), which was 
used for previously developed MB conjugated PAA NPs. [10] The new PEGDMA PAA 
NP also uses a smaller mole fraction of the cross-linker per nanoparticle, so as to further 
enlarge the average pore size of the NP matrix. The PEGDMA PAA NPs were 
conjugated with different amounts of MB, and then characterized. Their ROS 
productivity was investigated using two ROS sensing dyes, ADPA and Singlet Oxygen 
Sensor Green (SOSG), so as to determine the optimal MB loading for PDT. 
In addition, a new microfluidic chip was introduced for quick and reliable in vitro 
PDT tests. The microfluidic chip is a promising analytic device for screening PDT 
efficiency due to its low cost, high-throughput and ease of controlling the micro-
environment. [26,27] It should be noted that the therapeutic effect of PDT depends not 




estimation of the therapeutic efficacy difficult and lengthy. Regarding in vitro PDT tests, 
usually they are performed in chambered cover glasses, for one specific test condition per 
experiment, and it is difficult to increase the number of tests done simultaneously, using 
several NP samples, due to the limited illumination area of the laser light source. 
[10,19,21] It would be expensive to design an intense and monochromatic light source 
with a large enough illumination area; on the other hand, if multiple small light sources 
were used, it would be challenging to have  the same flux of the light source on each PDT 
test area. Thus, employing a new approach, batches of NPs with three different MB 
loadings were tested simultaneously on the microfluidic chip, so as to determine their cell 
killing efficacy by PDT. Also, this device allowed to perform several PDT efficacy tests 
under exactly identical test conditions (the same NP concentration, oxygen concentration, 
and homogeneous light illumination) while using only small amounts of test sample. 
Based on this, results for light illumination at half maximal inhibitory time (IT50) were 
derived by measuring cell survival at varying light illumination time periods, for given 
MB–PEGDMA PAA NP doses, using C6 glioma cancer cells. 
3.2 Experimental Section 
 Materials 3.2.1
Materials. Acrylamide (AA), poly(ethylene glycol) dimethacrylate, Mn 550, 
(PEGDMA), ammonium persulfate (APS), N,N,N’,N’- tetramethylethylenediamine 
(TEMED), sodium dioctylsulfosuccinate (AOT), Brij 30, dimethyl sulfoxide (DMSO), 
phosphate buffered saline (BioReagent, pH 7.4, for molecular biology), β-nicotinamide 




kluyveri (NADH dehydrogenase), Trichloro(1H,1H,2H,2H-perfluorooctyl)silane and 
hexane were purchased from Sigma-Aldrich. N-(3-aminopropyl)methacrylamide 
hydrochloride (APMA) was purchased from Polysciences. Dicarboxymethylene blue 
NHS ester (DCMB-SE) was purchased from European Molecular Precision Biotech. 
Singlet Oxygen Sensor Green (SOSG), 9,10-dipropionic acid disodium salt (ADPA), 
Dulbecco’s Modified Eagle Medium (DMEM),colorless DMEM (no phenol red), 100X 
Antibiotic-Antimycotic  and LIVE/DEAD
®
 Viability/Cytotoxicity Kits were purchased 
from Life Technologies. The water was purified with a Milli-Q system from Millipore 
Corporation.  SU8 2050 was purchased from MicroChem Corporation. 
Poly(dimethylsiloxane) (PDMS) kit (Sylgard 184) was purchased from Dow Corning 
Corporation. Glass slides were purchased from Fisher Scientific. All chemicals were used 
without further purification. 
 MB–PEGDMA PAA NPs Synthesis 3.2.2
Preparation of MB–PEGDMA PAA NPs. The MB–PEGDMA PAA NPs were 
prepared similarly to a previously reported MB–PAA NPs method. [10] A 100 µL of 
DCMB-SE solution (50 µg∙µL
-1
 in DMSO) was added to a monomer solution including 
368 mg of AA and 28 mg of APMA in 0.93 mL of PBS (pH 7.4). After 2 h incubation for 
MB conjugation with APMA, 53.4 µL of PEGDMA cross-linker was added into the 
monomer solution. The resultant monomer solution was then added into a 100 mL round 
bottomed flask containing 30 mL of deoxygenated hexane, 1.07 g of AOT and 2.2 mL of 
Brij 30 surfactants. To initiate radical polymerization, 100 µL of TEMED and 100 µL of 
APS (15% w/v) were added to the reaction mixture under inert conditions and stirred for 




to remove hexane, and washed with enough ethanol and pure water, using Amicon 
Stirred Ultrafiltratoin Cells (200mL, equipped with a Biomax 300,000 MWCO 
membrane). The washed MB–PEGDMA PAA NPs were freeze-dried and stored at -
20 °C. 
 Characterization 3.2.3
Characterization. The absorption spectra were taken on a UV-1601 UV-vis 
spectrometer (Shimadzu) and a FluoroMax-3 Spectrofluorometer (Jobin Yvon Horiba) 
was used for fluorescence spectra. For both spectra, 1 mg∙mL
-1
 of MB–PEGDMA PAA 
NPs solution in PBS (pH 7.4) was used. For the absorbance spectra, background 
absorbance from the scattering of PEGDMA PAA NPs was subtracted, using Origin 
program. Using the absorbance spectrum of MB–PEGDMA PAA NPs, the actual amount 
of MB content per NP was calculated, based on the calibration curve of MB-SE in PBS 
(pH 7.4). The differential intensity based averaged size distribution and the surface 
charge of the MB–PEGDMA PAA NPs were determined by dynamic light scattering 
(DLS) using a Delsa Nano C particle analyzer instrument (Beckman Coulter). 
Transmission electron microscopy (TEM) images of MB–PEGDMA PAA NPs were 
obtained on a Philips CM-100 transmission electron microscope, using uranyl-acetate 
staining on the grid. All of the measurements were triplicated. 
Detection of ROS (k and S value tests). The ROS produced from the MB–
PEGDMA PAA NPs was detected by using ADPA. A 2 mL of MB–PEGDMA PAA NPs 
solution (1 mg∙mL
-1
 in PBS (pH 7.4)), containing 80 µL of ADPA (100 µM in pure 
water), was irradiated at 660 nm, over different time periods (0, 60, 120, 180, 240, 300, 




spectra of ADPA, excited at 370 nm, were taken right after each irradiation time period. 
The ADPA decay constant, the “k value,” was calculated by the equation reported 
previously. [20,25] For the detection of
 1
O2 emanating from the NPs, a specific chemical 
probe, SOSG was used. [28-31] A 10 µL aliquot of SOSG (0.5 mM in MeOH) was added 
to a 2 mL MB–PEGDMA PAA NPs solution (1 mg∙mL
-1
 in PBS (pH 7.4)), under 
constant stirring and temperature (25 °C). Note that the free SOSG can be activated in a 
pH 7.4 solvent; thus, a “blank spectrum” of SOSG fluorescence (without singlet oxygen) 
was taken by irradiating at 504 nm. After taking a blank spectrum, the photosensitizer 
sample was irradiated for 5 min at 660 nm. The enhanced SOSG fluorescence spectrum 
(λex = 504 nm) was obtained immediately after stopping the irradiation of photosensitizer. 
The arbitrarily defined “S value” constant, for singlet oxygen production, was obtained 
by calculating the ratio of SOSG fluorescence comparing fluorescence before and after 
irradiation (enhanced/unenhanced). 
Enzymatic Reduction Test of MB–PEGDMA PAA NPs. The enzymatic reduction 
test of MB–PEGDMA PAA NPs was obtained based on our previous reported method. 
[19,21] In this test, NADH and diaphorase are mixed with MB. The diaphorase catalyzes 
oxidation of NADH, and the H
+
 released from the NADH reduces the MB, converting it 
into the lueko-MB that neither works as a photosensitizer nor fluoresces. Into 2 mL of 
12.1 nmol∙mg
-1
 of MB conjugated PEGDMA PAA NPs solution (1 mg∙mL
-1
 in PBS (pH 
7.4)), 133.6 µL of NADH (10 mg∙mL
-1
 in PBS (pH 7.4)) and 200 µL of diaphorase (1 
mg∙mL
-1
 in PBS (pH 7.4)) were added. The fluorescence emission signal of MB–
PEGDMA PAA NPs, excited at 660 nm, was monitored for 10 min, at 25 °C and under 




fluorescence emission signal of the same MB conjugated PEGDMA PAA NPs solution 
without NADH and diaphorase was monitored. This experiment was repeated with free 
MB solution and the measurements were conducted in triplicate. 
 In Vitro PDT through Microfluidic Device 3.2.4
Microfluidic Chip Preparation. The microfluidic chips were fabricated using a 
customized soft lithography process similar to what was reported earlier. [26,27] The 
replication mold was made of 170 µm thick negative photoresist on a silicone substrate. 
SU8 2050 (epoxy-based negative photoresist) is spin-coated at 1000 rpm, to reach the 
target thickness, and patterned with standard photolithography (UV dose 350 mJ∙cm
-2
). 
The resulting SU8 thickness is measured using a Dektak 6M surface profilometer (Veeco 
Instruments Inc.). Before applying PDMS, replication molds are coated with a self-
assembly monolayer (SAM) of Trichloro(1H,1H,2H,2H-perfluorooctyl)silane by 
vacuuming for 1 h in a desiccator. Then,  a mixture of PDMS prepolymer at a 10:1 ratio 
(base: curing reagent) was poured onto the mold and peeled off after curing under 100 °C 
for 1 h. Inlet and outlet reservoirs were punched out using 2 mm and 4 mm diameter 
biopsy punches (MedPlus Inc.). After an oxygen plasma treatment procedure (200 mTorr, 
50 W, 30 sec) was conducted on the surface, the PDMS microfluidic layer was bonded to 
a glass slide. A post-bake for 20 min at 90 °C was adopted for enhancing the permanent 
bonding between the PDMS and the glass, finalizing the assembly.  
Test of LED Light Illumination Uniformity on Microfluidic Chip. To test the 
uniformity of light illumination on the microfluidic chip, an LED lamp (625 (± 20) nm, 
Philips Lumileds) was placed 9 cm above the chip and used as a light source, instead of 




the PDT test. Then, a x2 bright field image of the microfluidic chip was obtained on a 
Nikon eclipse TE2000-U microscope (Nikon Instruments Inc.).  The grayscale intensity 
of the whole PDT tested area in each quadrant on the bright field image was measured 
and averaged by ImageJ program. 
Cell Culture and PDT Test on the Chip. The C6 rat glioma cells (CCL-107, ATCC) 
were cultivated in DMEM media with 10% heat inactivated fetal bovine serum (HI-FBS) 
and 1% 100x Antibiotic-Antimycotic (10,000 units∙mL
-1
 of penicillin, 10,000 µg∙mL
-1
 of 
streptomycin, and 25 µg∙mL
-1
 of Fungizone®). Prior to cell plating on the microfluidic 
chip, the chip was coated, using a solution of 0.01% collagen and 0.2% acetic acid in 
pure water, and incubated overnight at 37 °C. Thereafter, the chip was washed with 
DMEM media to remove any residual collagen solution, and the C6 cells were 
subsequently loaded into the microfluidic chip and cultured for about 24 h in the 





 or 12.1 nmol∙mg
-1
 of MB conjugated PEGDMA PAA NPs (0.2 
mg∙mL
-1
 in DMEM) were injected and the chip was covered by aluminum foil, to protect 
the sample from light. The remaining well of the microfluidic chip was not treated with 
NPs solution, and thus served as a control for each condition. After 10 min incubation, 
the chip was illuminated by LED light (625 (± 20) nm; 35.2 mW), for varying periods of 
time, ranging from 0 to 21 min, to deliver light doses of 0, 5.6, 11.2, 16.8, 22.4, 28, 33.6 
and 39.2 J∙cm
-2
 (Scheme 3-1). For 0 min light illumination, the NPs were incubated an 
extra 21 min (the same condition as for the longest light illumination times) without any 
light source as a dark toxicity test of NPs on C6 glioma cells. The distance between the 




the MB–PEGDMA PAA NPs solution was removed from the chip. Then, 50 µL of 
colorless DMEM solution containing 0.25 µL of calcein AM (2 mM in DMSO) and 0.25 
µL of ethidium homodimer-1 (2 mM in DMSO) were added to each well. After 10 min 
incubation, the fluorescence images of calcein AM (excited at 460 - 500 nm), and 
ethidium homodimer-1 (excited at 530 - 560 nm) were taken, using the Nikon Eclipse 
TE2000-U microscope. The numbers of live and dead cells in an x10 image were counted 
manually, and cell viability was calculated by equation 3-1 (eq. 3-1) below.  
 
Survivability (%) = 
                       
                                             









3.3 Results and Discussion 
 Characteristics of MB–PEGDMA PAA NPs  3.3.1
Based on the differential intensity (%) obtained by DLS, the hydrodynamic size of the 
MB–PEGDMA PAA NPs was 78.5 (± 5.8) nm (Figure 3-1). This is a larger size than the 
one previously reported for MB–AHM PAA NPs, 55.8 (± 5.0) nm. [10] The increased 
size of the NPs is attributed to the use of a longer cross-linker, PEGDMA (Mn 550), 
compared to AHM (MW 214). Furthermore, a reduced amount of cross-linker, from 13.6% 
to 2% (molar ratio of total monomer), may have also helped to increase the 
hydrodynamic size of the NPs, possibly due to a higher swelling ratio of the hydrogel, 
caused by the forming of fewer networks inside the NP matrix. [32] The size of the 
dehydrated MB–PEGDMA PAA NPs was checked by TEM imaging. Similar with 
previous reported hydrogel NPs, the dehydrated MB–PEGDMA PAA NP shrunk upon 
drying, its size being around 14 nm (Figure 3-2). [10,24] The surface charge of the MB–
PEGDMA PAA NPs was 23.0 (± 1.7) mV. This positive surface charge presumably 
originates from the primary amines, from the APMA monomer that was used for further 





Figure 3-1 DLS of MB–PEGDMA PAA NPs. 
 
 
Figure 3-2 TEM of MB–PEGDMA PAA NPs. 
 
The absorption spectra of the MB–PEGDMA PAA NPs, containing different amounts 
of conjugated MB, were obtained (Figure 3-3a). The MB–PEGDMA PAA NPs have their 
absorbance peak at 669 nm, which is the same position as for free DCMB-SE. Increasing 
the conjugated MB amount, another peak appears at 619 nm, which is due to aggregation 
of the MBs. [34-36] A significant dimer aggregate signal is observed, starting at 12.1 
nmol∙mg
-1
 of MB loaded PEGDMA PAA NPs, and at higher loadings. Under the same 




obtained (Figure 3-3b). There are strong excitation and emission signal peaks at 669 nm 
and 690 nm, respectively. The excitation peak wavelength matches exactly with the 
absorbance wavelength. Both the excitation and emission signals increased as more MBs 
are conjugated. However, these spectral intensities rather decreased from the 12.1 
nmol∙mg
-1
 of MB loading, which is the same MB loading point where the significant MB 
dimer absorbance peak was observed. Because of the large amount of MB dimers inside 
the NP matrix, there might be self-quenching of MB fluorescence, caused by interactions 
between excited states of MB molecules, and indeed a very low fluorescence signal was 
obtained, at the highest MB loading, 29.6 nmol∙mg
-1
, in PEGDMA PAA NPs. [10,18] 
 
 
Figure 3-3 (a) Absorbance spectra of MB–PEGDMA PAA NPs, as function of matrix 
concentration; (b) Fluorescence excitation (left peak) and emission (right peak) spectra of 
MB–PEGDMA PAA NPs, λex = 660 nm. 
 
 Advantages of MB–PEGDMA PAA NPs                                         3.3.2
According to our previous studies, the PAA nanomatrix protected the embedded MB 
molecules from undergoing reduction into a photo-inactive form, leuko-MB, due to an 




PAA NPs may have a larger pore size, due to having longer chains and reduced amounts 
of cross-linker, we believe that the pore size is still small enough to prevent the enzymes 
from entering into the NP matrix — to prevent the embedded MB from reduction. The 
efficiency of protection of MB from reduction was tested for the MB–PEGDMA PAA 
NPs by the enzyme reduction test. While less than 20% of the fluorescence intensity of 
free MB remained in the presence of NADH and diaphorase, more than 90% of MB 
fluorescence intensity in the PEGDMA PAA NPs remained under the same conditions 
(Figure 3-4). The 8% of fluorescence decrease of MB–PEGDMA PAA NPs is 
presumably caused by the MBs conjugated onto the surface of the PEGDMA PAA NPs, 
which are not well protected by the matrix, while most of the conjugated MBs residing 
deeper inside the NPs are protected by the nanomatrix. 
 
Figure 3-4 Enzyme reduction test of MB–PEGDMA PAA NPs: Free vs PAA 
encapsulated MB. 
 
In addition, the MB–PEGDMA PAA NPs have an advantage based on optical 
considerations. In the PDT experiment, it is very important to optimize the local 
concentration of the photosensitizer in the blood stream, or inside organs since the 




formation. [18] Hence, the in vivo production efficiency of ROS may be very different 
from the in vitro experimental value. In contrast with MB encapsulated in the nanomatrix, 
the PEGDMA PAA NPs attach their MB moieties by a conjugation method. MB–
PEGDMA PAA NPs essentially keep the same distances between MBs even when 
varying the NP concentrations, since the distances among the MBs are fixed by the 
chemical bonds within the PAA chain. In Figure 3-5, the absorbance spectra of MB–
PEGDMA PAA NPs do not change shape even at the higher NP concentrations. Thus one 




Figure 3-5 Absorbance spectra of MB–PEGDMA PAA NPs (12.1 nmol∙mg
-1
 MB 
loading) with varying NP concentration. The absorbance peak of the MB dimer is at 619 
nm and that of the monomer MB at 669 nm.  
 
 ROS Productivity Tests of MB–PEGDMA PAA NPs 3.3.3
Based on the k value test using ADPA, the ROS production efficiency of the MB–
PEGDMA PAA NPs was estimated and compared with the previous MB–AHM PAA 






 of MB loaded PEGDMA PAA NPs, where k = 13.4 x 10-4 s-1, and this k value 
maximum is 1.44 times higher than the maximum value found with MB–AHM PAA NPs, 
namely k = 9.3 x 10-4 s-1 at 8.8 nmol∙mg-1 of MB loaded sample. [10] In addition, to 
compare the required amounts of conjugated MB between the two different NPs for 
producing the same amount of ROS, the MB–AHM PAA NPs were reproduced. [10] The 
MB–AHM PAA NPs containing 3.0 nmol∙mg
-1
 of MB have a k value of 5.9 x 10-4 s-1 
while the MB–PEGDMA PAA NPs containing only 2.1 nmol∙mg
-1
 of MB produce a 
similar amount of ROS, i.e., with k = 6.0 x 10-4 s-1. These improvements presumably 
originate from a reduced amount of longer cross-linker, which increases the distances 
between MBs, resulting in reduction of self-quenching while also providing a larger pore 
size, which allows for better oxygen permeation and lower collision probability between 
the produced ROS.  
In Figure 3-6 (black line), the k value of the MB–PEGDMA PAA NPs decreases after 
peaking at 12.1 nmol∙mg
-1
 of MB loading, which may result from too high MB loading 
within the limited space of the PAA NPs. It is necessary for the produced ROS to escape 
from the nanomatrix in order to kill the cancer cell or, in our measurements here, to react 
with the external ROS detection probe. However, the overproduced ROS species could 
react among themselves before getting out of the PAA NPs, so the amount of ROS 
outside the NPs may decrease, rather. Moreover, the excited photosensitizers could be 
self-quenched at the highly concentrated MB loading inside the limited space of the NPs, 





Notably, the fluorescence emission spectra are determined by the amount of MB 
monomer, which is involved in producing 
1
O2. [18] However, the k value dependence on 
the total MB loading does not follow the trend observed in the fluorescence spectra 
(Figure 3-3b) in a simple way. The highest fluorescence intensity of the NPs was 
obtained at 5.5 nmol∙mg
-1
 of MB loading, not at the MB loading of the highest k value, 
which was 12.1 nmol∙mg
-1
. Furthermore, at 2.1 nmol∙mg
-1
 of MB loading, the NPs have 2 
times higher fluorescence intensity but 42% less k value than at 29.6 nmol∙mg
-1
 of MB 
loading. For finer discrimination, so as to detect only the 
1
O2, among all the ROS 
produced by the MB–PEGDMA PAA NPs, a singlet oxygen probe, SOSG was applied; 
SOSG reacts solely with 
1
O2 but not with other ROS such as superoxide radical anion or 
hydroxyl radical. [29-31] In the presence of singlet oxygen, it emits an enhanced 
fluorescence at 525 nm. The SOSG can be activated in a DMSO and PBS (pH 7.4) 
solvent, in which a blank SOSG fluorescence spectrum was first taken, i.e., without 
1
O2 
generation from MB–PEGDMA PAA NPs. Then, with the NPs included, the enhanced 
SOSG fluorescence intensity, which is due to the presence of 
1
O2, was taken, and the 
enhancement ratio was calculated, so as to give the “S value”. In Figure 3-6 (blue line), it 
can be seen that the maximal amount of 
1
O2 was produced at a loading of 5.5 nmol∙mg
-1
 
MB in PEGDMA PAA NPs. Also, the relationship between the fluorescence of MB–
PEGDMA PAA NPs and the S value was quite linear, which supports the hypothesis that 
1
O2 is produced overwhelmingly by the MB monomer, but not by the MB dimer (Figure 
3-7). Due to the small size of the ADPA and SOSG molecules, these dyes can penetrate 
into the nanoparticles and detect the ROS inside the PAA NPs platform. Because of this, 




However, the overestimation equally applies to all the tested NPs and the relative k and S 
values should not be affected. Thus, this potential overestimation will not distort the 
general trend of k and S values observed with various MB loadings in PAA NPs. 
 
Figure 3-6 The k and S values of MB–PEGDMA PAA NPs depend on the amount of 




Figure 3-7 Correlation of S value with fluorescence emission intensity of MB–PEGDMA 
PAA NPs based on Figure 3-3b. 
 
To find out the relationship of the k value and S value with the PDT effect of the MB–




group reported that not only the MB monomer but also the MB dimers produce specific 
ROS, through two major photochemical pathways, Type I and II (Scheme 3-2). [18,35-37] 
The MB monomer produces 
1
O2 by energy transfer to the oxygen molecule from the 




), Type II, while at the higher MB concentration, the 
dimer MB ((MB)2
2+
) produces semireduced MB radicals (MB
•
) by redox suppression of 
excited ground sate dimers, and the MB
•
 is oxidized to produce superoxide, Type I. 
Therefore we can explain why the higher MB loaded NPs (12.1, 15.8, 29.6 nmol∙mg
-1
) 
had a higher overall ROS production, compared to the lower MB loading case; the 
increase in superoxide radical production also affects the ADPA quenching rate, which 





Scheme 3-2 Schematic ROS producing routes of MB: MB monomer produces singlet 
oxygen (Type II) while MB dimer produces superoxide (radical anion) (Type I). Note: 





 PDT Efficacy Test Using Microfluidic Chips  3.3.4
To find out the relationship of ROS productivity based on the k and S values with the 
actual cell killing efficacy, an in vitro PDT test was performed using microfluidic chips. 
The chip was divided into four equal parts to increase throughput per test and it was 
illuminated homogeneously by the same light source. Through a gray scale test of the 
microfluidic chip’s bright field image, the homogeneity of the LED light illumination 
was confirmed for the microfluidic chip under test. The averaged gray scale exhibited a 
very similar intensity, around 2300 (arbitrary units) for each quadrant in the microfluidic 
chip (Figure 3-8). In Figure 3-9, it shows cell survival data, for three different MB 
loadings, under a fixed NP concentration of 0.2 mg∙mL
-1
, based on a live/dead cell assay, 
as a function of light illumination time. The MB–PEGDMA PAA NPs of the three 
different MB loadings (2.1, 5.5 and 12.1 nmol∙mg
-1
) were investigated vs. a control of C6 
cells without any NP treatment. Notably, based on “0 min” and “control” cases, no cell 
death was induced by light without NPs, nor by NPs without light. The k and S values 
exhibit significantly different trends in the MB loading range of 5.5 to 12.1 nmol∙mg
-1
. 
As expected for this loading range, the 2.1 nmol∙mg
-1
 MB loaded NPs which have the 
lowest k and S values among three samples took the longest times, 21 min, to kill all of 
the C6 cells. In addition, with the 5.5 nmol∙mg
-1
 of MB loaded NPs, it took 12 min to kill 
the C6 cells, but only 9 min was taken for killing most of the cells when using the 12.1 
nmol∙mg
-1
 of MB loaded NPs (Figure 3-9a). This trend clearly corresponds with the k 
value, not the S value, and is expected since not just the 
1
O2 but also the superoxide 
radical anion contributes to the killing of the cells. [18,38] In addition, the half maximal 




based on Figure 3-9b, and it shows a linear relationship with the k value (Figure 3-10). 
This supports the hypothesis that the relative trend of the detected k values is not 
distorted by potential overestimation of the absolute values. Using this trend, the IT50 for 
different MB loaded NPs could be estimated. 
 
 
Figure 3-8 Averaged bright field image intensity on microfluidic chip illuminated by 







Figure 3-9 (A) Fluorescence images, with calcein AM and ethidium homodimer-1, for 
determining the viability of C6 cells, after PDT treatment using MB–PEGDMA PAA 
NPs, with varied MB concentration (2.1, 5.5, 12.1 nmol∙mg
-1
) and illumination time (0 – 
21 min). The green color identifies a live cell (calcein AM) and the red color a dead cell 
(ethidium homodimer-1); (B) Cell viability (%) of A (a-c) based on eq. 1 (n = 3). 
 
 




3.4 Conclusions  
In summary, a revision in synthetic approach of MB loaded PAA NPs coupled with 
improved analytical methods resulted in more efficient PDT. The PEGDMA cross-linked 
PAA NPs were designed for a higher PDT efficacy. Because of the longer cross-linker, 
PEGDMA, this novel NP matrix provides an increased distance among the conjugated 
MB photosensitizer groups, so as to control/minimize the aggregation of MB moieties 
inside the NPs reducing collision probability among the produced ROS and providing 
higher oxygen permeability. Such control of aggregation can serve as a tuning 
mechanism for the produced ROS mixture. At the same time, the PEGDMA PAA NPs 
matrix prevents any leaching out of the MB photosensitizer; protects it from reduction by 
plasma enzymes as tested in the presence of NADH with diaphorase even with increased 
pore size, and also preserves its spectral shape at both low and high concentrations.  
The ROS productivity was measured using both k and S values, respectively obtained 
from the ROS sensitive ADPA probe and from the singlet oxygen sensitive SOSG probe. 
An excellent correlation was found between the MB monomer fluorescence peak 
intensity and the singlet oxygen production (S value), as well as between the k value and 
the total ROS production. Based on the k value, 1.44 times more ROS was produced by 
the new MB–PEGDMA PAA NPs, relative to the previous generation’s MB–AHM PAA 
NPs, when comparing them at the most optimized MB loading for each NP. In addition, 
using the MB–PEGDMA PAA NPs saves 30% of the costly MB-SE needed to produce 





A microfluidic device optimized for in vitro PDT was developed so as to enable 
reliable quantitative measurements of the PDT efficacy of MB–PEGDMA PAA NPs. 
Because of the small size of the chip, the LED illumination could be provided 
homogeneously, making it possible to reliably compare several different NPs 
simultaneously. The highest measured k value for the MB–PEGDMA PAA NPs, k = 
13.4x10-4 s-1 (at 12.1 nmol∙mg-1 MB loading), correlates with the most rapid killing of the 
C6 cancer cells (IT50 = 6.6 min) and a linear relationship was found between this 
traditional k value and the IT50 for PDT cell killing. This confirms the accepted, but 
sometimes overlooked, notion that PDT is not just due to singlet oxygen, but a result of 
various ROS, and that the ROS composition/mix may be important, as well as the ability 
of tuning this composition/mix.  
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PHOTO-MODULATION OF HEART RHYTHM: CELL SELECTIVE 
ARRHYTHMIA ABLATION USING TARGETED NANOPLATFORMS 
4.1 Introduction 
Heart disease is the primary cause of death in developed countries, and is 
overwhelmingly correlated with rhythm anomalies, i.e., arrhythmias. [1,2] The heart 
rhythm and its failures are controlled by myocytes which account for 2-3 billion cells in 
each heart. [3] The cardiac myocytes are the excitable cells that form an electrical 
syncytium and enable heart contraction and dilation. [4] Other cells include 1) fibroblasts 
and other connective tissue cells, 2) nerve cells, 3) smooth muscle and endothelial cells of 
the coronary vasculature and endocardium, 4) mast cells as well as stem cells and 
pericytes. [3,5]  
 Disturbances of the myocyte-generated electrical impulse may result in the formation 
localized self-perpetuating arrhythmia sources. [6] Most arrhythmias are associated with 
substantial morbidity and mortality and represent an ever-growing therapeutic challenge. 
Arrhythmia management generally includes either anti-arrhythmic drugs and/or 
interventional procedures, such as surgery and catheter ablation. [7,8] In the last decades, 
catheter ablation has emerged as a common procedure employed in the hospital setting. 
Ablation technologies implement ablative energy delivered locally to cardiac regions 
harboring electrical sources of arrhythmia. Energies commonly employed are 
radiofrequency, cryoenergy, light amplification by stimulated emission of radiation 




ablation technique is highly unspecific; all bystander cells are damaged along with the 
myocytes. [9] In addition, the catheter ablation technique is complex and difficult, and 
carries with it many risks, such as atrioesophageal fistula, pulmonary veins stenosis, 
coronary artery injury, tissue edema, thrombus formation and steam. [10-14]  
To overcome the disadvantages of the existing catheter ablation technique, we have 
developed a nanoplatform enabled photodynamic therapy (PDT) which is a clinically 
approved localized phototherapy which has been tested for several medical conditions, 
especially cancer diseases. [15] During the PDT treatment, the photosensitizer, excited by 
illumination from an appropriate wavelength light source (e.g., laser), produces cytotoxic 
reactive oxygen species (ROS), resulting in tissue damage. [15,16] In a previous in vitro 
study, 50-60 nm sized methylene blue (MB) loaded polyacrylamide nanoparticles (MB‒
PAA NPs) were prepared as a PDT nano-drug and showed high efficacy in killing cancer 
cells. [17] Furthermore, conjugating the cardiac targeting peptide (CTP) to these NPs, 
cell selectivity was achieved in vitro, i.e., killing only the myocytes, but not the 
fibroblasts. [9] However, in vivo, the size of the cardiac capillary vessels’ fenestrations 
(pores) is highly limited (range 6-25 nm). [18-21]  
Thus, a new nanoplatform had to be engineered, so as to have the ability to pass 
through the in vivo heart endothelial structure and be delivered to cardiac myocytes. 
Among available biocompatible materials, we chose the FDA (Food and Drug 
Administration) approved polyethylene glycol (PEG) material, with its low toxicity, 
enhanced plasma circulation time, reduced proteins fouling and chemical versatility. [22-
24] We adapted a star shaped 8-arm PEG supramolecule so as to enable the attachment of 




to achieve both therapeutic and targeting functionalities. [25,26] A photosensitizer, Ce6 is 
a natural product derived from the chlorella species and has high optical absorption in the 
near infrared, a wavelength which deeply penetrates into living tissues. [27,28] The CTP, 
a nontoxic 12 amino acid targeting moiety (APWHLSSQYSRT), provides cell targeting 
specificity for myocytes. [9] 
In this chapter, we report on 1) a synthetic strategy to prepare the CTP modified Ce6 
conjugated 8-arm PEG nanoplatform (CTP‒Ce6‒PEG) and its characterization; 2) 
successful selective myocyte killing by in vitro PDT; and 3) CTP‒Ce6‒PEG targeting to 
the myocytes in a live rat, as well as selective cardiac ablation by in vivo PDT on live 
hearts. 
4.2 Experimental Section 
 Materials 4.2.1
Materials. 8-arm polyethylene glycol-amine (8-arm PEG, 40 kDa and 
heterobifunctional polyethylenegylcol (Mal-PEG-NHS, 2 kDa) were purchased from 
Creative PEG Works. N,N′-dicyclohexylcarbodiimide (DCC), N-hydroxysuccinimide 
(NHS), N,N-dimethylformamide (DMF), phosphate buffered saline (BioReagent, pH 7.4, 
for molecular biology), bovine serum albumin (BSA) medium 199 (M199), sodium 
chloride (NaCl), potassium chloride (KCl), 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES), potassium phosphate dibasic anhydrous 
(K2HPO4), magnesium sulfate (MgSO4), glucose, calcium chloride (CaCl2) glutathione, 
sodium bicarbonate (NaHCO3) and Monoclonal Anti-Vimentin−Cy3 antibody were all 




Frontier Scientific. Cardiac targeting peptide with cysteine attached (CTP−Cys, 
APWHLSSQYSRTC, > 95%, 1535.7 Da) was purchased from RS synthesis. Anthracene-
9,10-dipropionic acid disodium salt (ADPA), calcein AM, propidium iodide (PI), 
penicillin-streptomycin, Dulbecco's Modified Eagle Medium (DMEM), 4′,6-diamidino-2-
phenylindole (DAPI) and 0.05% trypsin-EDTA were purchased from Life Technologies. 
Blebbistain was purchased from Cayman Chemical. Collagenase II was purchased from 
Worthington Biochemicals. Anti-heavy chain cardiac Myosin antibody (clone # 3-48) 
and Alexa fluor 488 were purchased from abcam. The water was purified with a Milli-Q 
system from Millipore. All chemicals were used without further purification. 
 Synthesis of the Nanomatrix 4.2.2
Preparation of Ce6 conjugated 8-arm PEG (Ce6‒PEG). The Ce6 was conjugated 
to amine groups of the 8-arm PEG through DCC and NHS coupling. The 448 µL of Ce6 
solution (20 mg∙mL
-1
 in DMF) was activated with 154.8 µL of DCC (20 mg∙mL
-1
 in 
DMF) and 172.8 µL of NHS, 20 mg∙mL
-1
 in DMF by stirring for 30 - 45 min. The 8-arm 
PEG solution (40 kDa, 20 mg∙mL
-1
 in DMF) was prepared by stirring and sonicating until 
the entire 8-arm PEG was dissolved. The prepared NHS activated Ce6 solution was 
added into a PEG solution and stirred overnight. To remove unreacted Ce6, the crude 
product was washed with 60% ethanol, PBS (pH 7.4) and D.I. water using an Amicon 
filtration system (10 kDa filter membrane). After the washing, the Ce6‒PEG was filtered 
by a 0.45 nm syringe filter and stored after freeze drying (Scheme 4-1). 
Preparation of CTP targeted Ce6‒PEG (CTP‒Ce6‒PEG). For the CTP targeting, 
1.47 mL of MAL-PEG-NHS (100 mg∙mL
-1
 in PBS (pH 7.4)) was added into 5 mL of 
Ce6‒PEG (20 mg∙mL
-1




centrifugal cell (10 kDa), the unreacted MAL-PEG-NHS was washed out three times and 
the concentration of nanoplatform solution was diluted to 20 mg∙mL
-1
 with PBS (pH 7.4). 
Then, 537 µL of CTP solution (100 mg∙mL
-1
 in PBS (pH 7.4)) was added into the 
nanoplatform solution under constant stirring. After overnight, 0.43 mL of cysteine (10 
mg∙mL
-1
 in D.I. water) was added and stirred 1 h additionally. The mixture was washed 
with enough D.I. water through an Amicon centrifugal cell (10 kDa) and the final CTP‒
Ce6‒PEG was obtained through freeze drying (Scheme 4-1). 
 
Scheme 4-1 Synthesis of CTP–Ce6–PEG nanoplatform. 
 
 Characterization 4.2.3
Absorbance & Fluorescence Measurements. To monitor the absorption and 
fluorescence spectrum of the nanomatrix, a UV-1601 UV-vis spectrometer (Shimadzu) 
and a FluoroMax-3 Spectrofluorometer (Jobin Yvon Horiba) were used. The nanomatrix 
solution was prepared (0.1 mg/mL) in PBS (pH 7.4). The measurements were conducted 
in triplicate. 
Detection of ROS. The ROS produced from CTP‒Ce6‒PEG were measured based on 
a previously reported method. [29] To 2 mL of CTP‒Ce6‒PEG (0.1 mg∙mL
-1
 in PBS (pH 




(λex = 370 nm) measured by a FluoroMax-3 Spectrofluorometer (Jobin Yvon Horiba), 
right after irradiation at 660 nm of the CTP‒Ce6‒PEG solution, over several time periods 
(0, 60, 120, 180, 240, 300, 480 and 660 sec), under constant stirring and temperature 
(25 °C). The decay constant of the ADPA fluorescence, the “k value” was calculated by 
the previously reported equation. [29] 
 Animal Tests 4.2.4
Isolation of Adult Rat Myocytes and Fibroblasts. Adult cardiomyocytes from 
normal adult male rats (200–300 g) were isolated as described before. [30] Briefly, after 
euthanasia, hearts were retrogradely perfused through the aorta for up to 5 minutes with 
modified Krebs-Henseleit buffer (KHB), containing NaCl (118 mM), KCl (4.8 mM), 
HEPES (25 mM), K2HPO4 (1.25 mM), MgSO4 (1.25 mM), glucose (11 mM) and CaCl2 
(1 mM), at pH 7.40. The perfusate was then switched to modified a Krebs buffer without 
calcium for 3 minutes. Following the calcium-free KHB perfusion, hearts were digested 
by perfusing calcium-free KHB containing 200 units/ml collagenase II, and blebbistatin 
(33.3 µM) for 15 min. The collagenase digested hearts were removed from the apparatus 
and the tissue was minced gently to separate out the cells. The suspension was 
centrifuged (500×g) for 30 sec, and the cell pellet was resuspended in KHB-A containing 
2% bovine serum albumin and blebbistatin. The cell suspension was centrifuged again 
and resuspended in culture media (M199) containing glutathione (10 mM), NaHCO3 (26 
mM), 100 units∙mL
-1
 penicillin, 100 µg∙mL
-1
 streptomycin and 5% fetal bovine serum. 
Cells were plated on laminin coated (40 µg∙mL
-1
) tissue culture cover slips. After 2 h, the 
medium was changed to serum-free M199. Cell suspension supernatant from both spins 




rpm for 10 min, and the cell pellet was suspended in DMEM supplemented with 1% 
penicillin-streptomycin and 10% fetal bovine serum (full medium). Cardiac fibroblasts 
were grown in a similar full medium until 70–80% confluent and passaged using 0.05% 
trypsin EDTA.  
In vitro PDT Test. The myocyte and fibroblast cells were co-cultured. The co-
cultures were incubated with free Ce6 (0.0016 mg∙mL
-1
) or CTP‒Ce6‒PEG (0.1 mg∙mL
-1
) 
for 2 h and washed with PBS (pH 7.4) three times. Using a Nikon A1R confocal 
microscope (Nikon Instruments Inc.), the nanoplatforms were activated by laser 
illumination at 405 nm (7-10 mW) over 10 min. After the illumination, co-cultured cells 
were treated by calcein AM and PI, as a live-dead cell assay. The fluorescence images 
measured of calcein AM and PI were taken by confocal microscope.  
Histology and Imaging. Immuno-fluorescence analysis was carried out on paraffin 
embedded tissue samples which were sectioned into slides. The following antibodies 
were used for the staining: 1) Myocytes - Anti-heavy chain cardiac Myosin antibody 
(clone # 3-48) with Alexa fluor 488 tagged secondary antibody, 2) Fibroblasts - 
Monoclonal Anti-Vimentin−Cy3 antibody (dilution 1: 100). DAPI was used to 
counterstain the nuclei. Primary and secondary antibodies were diluted in PBS (pH 7.4) 
plus 0.1% Triton X-100 and 5% donkey serum. Images were acquired using a Nikon A1R 
confocal microscope with sequential laser firing.   
Open Chest Rat Model, Protocol and Analysis. All procedures were approved by 
the University of Michigan Committee on Use and Care of Animals and complied with 
the National Institutes of Health guidelines. We used male Sprague–Dawley rats 




12 h light-dark cycle. The animals were anesthetized with ketamine (60 mg∙kg
-1
 IP) and 
xylazine (6 mg∙kg
-1
), placed in dorsal recumbency, and then intubated and ventilated 
throughout the procedure with 100% humidified oxygen at 90 strokes∙min
-1
 and 10 
mL∙kg
-1
 tidal volume. An extra dose of anesthetic (one third of the initial dose of 
ketamine) could be administered as needed at 45 min after the first dose to prolong 
anesthesia. Limb electrodes are placed and connected to an amplifier to record EKG 
continuously. With the animal in dorsal recumbency, the skin on the ventral thorax is 
shaved and disinfected and then is incised at the left thorax, lateral to the sternum near 
the third intercostal space. After incising intercostal muscle, the left atrium is exposed 
and held with the help of retractors. The animal is allowed to stabilize for 15 min. A 
bipolar electrode is placed on the left atrial appendage (LAA) and the amplitude is 
recorded. Then the laser (671 nm, 300 mW) light is directed onto the left atrial appendage 
for 4 minutes. This served as a control to evaluate the possible effects on the electrogram 
amplitude with laser illumination alone. Then, 2 mL of CTP‒Ce6‒PEG (50 mg∙mL
-1
 in 
PBS (pH 7.4)) is injected into the tail vein. After 60 min, following CTP‒Ce6‒PEG 
injection, the laser is directed towards the LAA, and the changes in LAA electrogram 
amplitude recorded (Scheme 4-2). Rats were injected with a dead cell stain - propidium 
iodide (PI) - via the tail vein (40 mg∙kg
-1
 body weights, in 1 mL PBS (pH 7.4)) for group 
2. After the experiment, the animal is euthanized and the heart is stored in formalin for 
histological analysis. For LAA amplitude analysis, bipolar recordings were filtered to 
eliminate AC power noise (60 Hz IIR band stop). The amplitude from the baseline is 
derived for the atrial signal and measured as difference of voltage between negative peak 





Scheme 4-2 Simplified scheme of the rat open chest PDT experimental set-up for  in vivo 
PDT test. 
4.3 Results and Discussion 
 Characteristics of the CTP‒Ce6‒PEG 4.3.1
CTP‒Ce6‒PEG absorbance and fluorescence spectra are shown in Figure 4-1, (a) and 
(b) respectively. In PBS (pH 7.4) buffer, free Ce6 has three absorption peaks, at 403 nm, 
505 nm and 655 nm. In comparison, Ce6‒PEG shows three shifted absorption peaks at 
401 nm, 502 nm and 660 nm. In particular, the peak around 660 nm of Ce6‒PEG 
indicates a significant red shift compared to free Ce6. The Ce6 content in the 8-arm PEG 
was calculated based on a free Ce6 absorbance calibration curve. It was found that 2.2 (± 




average of about 1.5 (± 0.1) molecules of Ce6 is conjugated per one 8-arm PEG 
nanoplatform. As shown in Figure 4-1b, free Ce6 excitation and fluorescence emission 
spectra appear at 655 nm and 660 nm (λmax), while the Ce6‒PEG peaks are shifted to 660 
nm and 663 nm (λmax), respectively. Both excitation maxima correspond to the analogous 
absorbance maxima, at around 660 nm, of the Ce6‒PEG and free Ce6 solution. 
Importantly, the fluorescence emission of Ce6‒PEG shows a higher intensity than free 
Ce6, with a similar Ce6 concentration.  
The targeting moiety, CTP, was conjugated to the surface of the Ce6‒PEG. After 
CTP conjugation, the absorbance and fluorescence spectra of 0.1 mg∙mL
-1
 of CTP‒Ce6‒
PEG decreased, presumably just due to its increased molecular weight (Figure 4-1). 
Based on the assumption that the entire bi-functional PEG was conjugated to CTP, the 
average number of CTPs per one PEG molecule was calculated from the ratio of the 
CTP‒Ce6‒PEG and Ce6‒PEG absorbance spectra. Accordingly, an average of 4.4 (± 1.2) 
CTP molecules was conjugated per one 8-arm PEG molecule, with an expected 
molecular weight of around 56.2 kDa. For the behavior of these nanoplatforms under 
biological conditions, the hydrodynamic size is very important, since the CTP‒Ce6‒PEG 
should be small enough to penetrate through the pores of the normal heart endothelial cell 
membrane. Following the hydrodynamic size dependence on the molecular weight for 
various proteins, the hydrodynamic size of the CTP‒Ce6‒PEG is estimated at 6.7 (± 0.9) 
nm. [31,32] However, it shouldn’t be overlooked that the CTP‒Ce6‒PEG, due to its star-






Figure 4-1 (a) Absorbance spectra CTP–Ce6–PEG; (b) Fluorescence excitation (left peak) 
and emission (right peak) spectra of CTP–Ce6–PEG, λex = 660 nm. 
 
To confirm the amount of produced ROS from the Ce6‒PEG, the “k value” was 
determined by calculating the first order decay kinetics of the ADPA’s oxidative 
quenching (Figure 4-2). [17,29] For 0.1 mg/mL of Ce6‒PEG in PBS (pH 7.4), the k value 
was found to be 2.99×10
-4
, but the k value for the same amount of free Ce6 in a test 
solution of Ce6‒PEG was only 2.12×10
-4
. This increase is presumably due to the 
bulkiness of the 8-arm PEG which helps to increase the distance between the fluorescent 
dye moieties; this may reduce the self-quenching rate of Ce6, thus increasing both the 
fluorescence yield (Figure 4-1b) and also the singlet oxygen productivity. We note that an 
about 4.5 times higher amount of ROS was produced from these Ce6‒PEG 
nanoplatforms than from the same total nanoplatform mass of the previously reported 






Figure 4-2 Efficiency of singlet oxygen production. Fluorescence spectra of ADPA with  
Ce6‒PEG solution (left) and fluorescence change of ADPA with linear fitted graph 
dependence on irradiation time of Ce6‒PEG, λex = 660 nm. 
 
 In Vitro PDT of Cardiac Ablation Using CTP‒Ce6‒PEG 4.3.2
We first tested the cell specific in vitro PDT efficiency of the CTP–Ce6–PEG. Co-
cultures of isolated adult rat ventricular myocytes and fibroblasts were obtained, as 
detailed in the experimental section. The cells in the co-culture were treated by PDT in a 
medium containing 0.0016 mg∙mL
-1
 of free Ce6 or 0.1 mg∙mL
-1
 of CTP–Ce6–PEG, in the 
presence of live/death indicator reagents, i.e., calcein-AM, for designating live cells, and 
PI, for designating dead cells. Under laser illumination, for free Ce6, both myocytes and 
fibroblasts exhibited rapid morphological changes with progressively increasing PI 
uptake (red fluorescence) and vanishing calcein-AM staining (green fluorescene), clearly 
indicating cell death (Figure 4.3a). However, for CTP–Ce6–PEG, only myocytes 
exhibited rapid morphological changes, from a rod-like shape to a random shrunken 
shape with emerging red PI fluorescence; in contrast, the fibroblast showed no such 
changes (Figure 4-3b). In addition, even when two different cell types came into contact 
with each other, the myocyte selectivity of the PDT damage caused by the targeted CTP–





Figure 4-3 Targeted PDT in in vitro co-culture of primary adult rat ventricular myocytes 
and cardiac fibroblasts; (a) non-selective ablation of free Ce6; (b) selective myocyte 
ablation of CTP–Ce6–PEG; (c) selective myocyte ablation of CTP–Ce6–PEG for 
contacted two different cell types. 
 
 In Vivo PDT of Cardiac Ablation Using CTP‒Ce6‒PEG 4.3.3
We evaluated the ability of the CTP–Ce6–PEG to achieve myocytes-specific ablation 
in vivo. We injected nanoplatform samples into 2 groups of rats: to confirm CTP–Ce6–
PEG delivery and myocyte-specific affinity (group 1) and to test myocyte-specific photo-
ablation (group 2). All rats were injected via the tail vein, with CTP–Ce6–PEG (1.6 mg 
Ce6/rat).  
In group 1, 1 h after injection of the nanoplatforms, the hearts were isolated and 
immuno-stained for myocytes and for fibroblasts, as described in the experimental 
section. From the co-localization study of confocal microscopy, the affinity of CTP–Ce6–




In Figure 4-4a, the image shows co-localized fluorescence of myocyte staining with Anti-
heavy chain cardiac Myosin antibody (green), fibroblast staining with Monoclonal Anti-
Vimentin-Cy3 antibody (yellow), Ce6 from CTP–Ce6–PEG (purple) and nucleus 
counterstaining with DAPI (blue). After removing (filtering out) the green color for 
myocyte staining, there was purple fluorescence observed, from the CTP–Ce6–PEG 
(Figure 4-4b). This stands for the CTP–Ce6–PEG that penetrated the heart endothelial 
structure and got attached to the myocytes. In Figure 4-4c, however, after filtering out the 
yellow fibroblast staining, we cannot observe any purple fluorescence from the CTP–
Ce6–PEG in the previously yellow fluorescence locations of the fibroblast. Thus, this 
study clearly shows that the CTP–Ce6–PEG nanoplatform is small enough to pass the 
heart endothelial structure as well as showing the selective affinity of the CTP–Ce6–PEG 
nanoplatform towards only myocytes, but not towards fibroblasts. 
 




In group 2, 1 h after CTP–Ce6–PEG injection, PDT ablation was performed in 
anesthetized rats. After left lateral thoracotomy and exposure of the left atrium, 300 mW 
of 671 nm LASER light was directed towards the left atrium, with 10-15 minutes of total 
illumination, Scheme 4-2. An LAA electrogram amplitude was continuously recorded 
during the experiment with a bipolar electrode positioned directly onto the LAA. Laser 
illumination led to rapid myocardial ablation as indicated by a progressive amplitude 
decrease in the LAA electrogram with local signal amplitude decreasing by about a factor 
of 6 after PDT (82.8 ±7.3% decrease, p < 0.05, n = 5) (Figure 4-5a).  Results were 
compared with the sham experiments (control), in which a similar protocol was followed 
but in the absence of CTP–Ce6–PEG injection; it was observed that the LAA local 
electrogram amplitude did not significantly change after laser illumination (9.08 ± 3.8% 





Figure 4-5 In vivo targeted photodynamic therapy and LAA electrogram amplitude 
recordings. After one hour of injecting CTP‒Ce6‒PEG, the laser (671 nm, 300 mW) light 
is shined on the LAA. The LAA electrogram amplitude is continuously recorded 
throughout the experiment, from a bipolar electrode placed directly on the LAA. (a) LAA 
electrogram with CTP‒Ce6‒PEG nanoplatforms; (b) LAA electrogram without 
nanoplatforms. 
 
After cell specific PDT ablation, we used a histology study to determine whether only 
myocytes, not fibroblasts, were ablated by PDT. Figure 4-6 shows strong PI intensity (red 
fluorescence, dead cell staining) at the nuclei located at the center of myocytes (green 
fluorescence) for ablated sites, while strong DAPI (blue fluorescence, counterstaining) is 
observed at the nuclei of fibroblasts, which are non-ablated sites. The significant 
fluorescence intensity change of DAPI and PI between the nucleus of a fibroblast and a 
myocyte (from star mark to diamond mark) was graphically presented in Figure 4-6d. 




Monoclonal anti-vimentin-Cy3 antibody and PI. In this histology study, we confirmed 
that only myocytes were ablated by in vivo PDT, not fibroblast 
 
Figure 4-6 Enlarged confocal fluorescence image of ablation site after in vivo PDT. a) 
Co-localized fluorescence image for Anti-heavy chain cardiac Myosin antibody and 
Alexa fluor 488-tagged secondary antibody stained myocytes (green fluorescence), DAPI 
stained nuclei of unablated cells (blue staining), and PI stained nuclei of ablated cells (red 
staining); b) isolated fluorescence image of DAPI stained nuclei for unablated cells 
(fibroblast); c) isolated fluorescence image of PI stained nuclei for ablated cells 
(myocytes); and d) fluorescence intensity profiles for each of three color stainings along 
yellow arrow in Figure 4-6a. 
4.4 Conclusions 
The above results strongly support the feasibility of a myocyte-specific photo-
ablation approach. The use of a myocyte-targeted PDT-enabled nanoplatform (CTP‒
Ce6‒PEG), which satisfies several requirements for cardiac PDT: 1) small size, 2) 
hydrophilicity, 3) no dark toxicity, 4) facile multiple modifications (conjugating with 
both Ce6 and CTP) and 5) low price, has been shown as a sound approach for modulating 




successfully targeted and killed only the myocytes. Furthermore, the CTP‒Ce6‒PEG is 
small enough to penetrate the cardiac capillary vessels’ pores and the selective targeting 
ability of these nanoplatforms towards myocytes was retained during the in vivo PDT, in 
order to ablate myocytes while preserving the integrity of the bystander cells. Also, this 
work sets the stage for the development of similar ‘alternative’ approaches to common 
cardiac ablation. It has been suggested that nerve terminals or Purkinje myocytes play a 
critical role in arrhythmia initiation. [33-36] Still, with traditional methods, it is nearly 
impossible to target these structures without affecting other cardiac cells. Potentially, 
treatment similar to our cell-specific technology could be implemented in well-defined 
clinical scenarios, as a stand-alone or as an adjuvant therapy. In our view, cell-specific 
photo-ablation could advantageously complement current ablation systems, with the dual 
goal of decreasing procedure time and decreasing complications and thus increasing 
efficacy. 
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CONCLUSIONS & FUTURE DIRECTIONS 
5.1 Conclusions 
There have been many efforts by scientists in a variety of biomedical fields to 
develop nanoplatforms for practical biomedical applications. Concerning the first and 
second highest causes of death (heart and cancer diseases) in the United States, this 
dissertation presented three different engineered nanomatrixes, aimed at biomedical 
imaging of cancer and at photodynamic therapy of cancer and of heart arrhythmia.  
In Chapter 2, a synthetic method was addressed to prepare human serum albumin 
(HSA) loaded polyacrylamide (PAA) nanoparticles (NPs) to enhance the stabilization of 
Indocyanine Green (ICG), which was loaded into NPs through a post-loading 
modification. The F3 peptide was conjugated onto the NPs with the help of a bi-
functional polyethylene glycol (PEG) as a cross-linker. To avoid blockage of the binding 
site, the bi-functional PEG was conjugated onto the NP surface before the ICG was 
loaded. The F3 peptide was then conjugated at the other end of bi-functional PEG. Due to 
the hydrophobic pockets in HSA, which hold the ICG strongly, the degradation rate of 
ICG was decreased and its thermal- and photo-stability increased compared to ICG in 
PAA NPs or to free ICG. With regards to the photoacoustic signal, an intense signal was 
observed at 720 nm, which corresponds to the ICG dimer, because of its lower 




monomer. In addition, these new protein hybrid PAA NPs showed cell specificity for the 
9L glioma cancer cell line, due to the F3 peptide targeting moiety. 
In Chapter 3, enhanced reactive oxygen species (ROS) producing Methylene Blue 
(MB) conjugated PAA NPs and a multiplexed microfluidic device for photodynamic 
therapy (PDT) analysis were introduced. The long cross-linker, poly(ethylene glycol) 
dimethacrylate (PEGDMA, Mn = 550), was used to increase the distance between the 
conjugated MB groups; it also provided high oxygen permeability. The MB‒PEGDMA 
PAA NPs advantages are expressed in higher ROS production rate than previously 
reported NPs, in protecting the loaded MB from bio-enzymes and in keeping the spectral 
shape of MB consistent at varied sample concentrations. During PDT, the relative total 
ROS production (k value) and the relative singlet oxygen generation (S value) of MB‒
PEGDMA PAA NPs with varied MB loading were detected using 9,10-dipropionic acid 
disodium salt (ADPA) and Singlet Oxygen Sensor Green (SOSG) dyes, respectively. The 
different trend of the k and S values originates from two distinct ROS producing routes of 
MB: the MB monomer produces singlet oxygen, whereas the MB dimer produces 
superoxide. The specially designed microfluidic chip, optimized for in vitro PDT efficacy 
tests, enabled simultaneous multiple measurements on different NP samples. This new 
microfluidic device helped not only to decrease the experiment time, the required sample 
amount and the cost, but also allowed a more accurate comparison of PDT efficacy 
between different photo-drug samples. 
In Chapter 4, a selective cardiac ablation for heart arrhythmia was achieved by a 
cardiac targeting peptide (CTP) targeted Chlorin e6 (Ce6) conjugated 8-arm PEG (Ce6‒




polymeric nanoplatform instead of PAA NPs due to the size limitation of heart tissue 
fenestrations (pores). During in vitro PDT, only myocytes, but not fibroblasts, were killed 
under the co-cultured condition. In contrast to the PAA NPs, the CTP‒Ce6‒PEG 
nanoplatforms are able to penetrate into the endothelial structure of heart, in vivo. Thus, 
in the histology test, the fluorescence of Ce6 was observed from myocyte cells, but not 
from fibroblast cells. During the in vivo PDT test, the left atrial appendage (LAA) 
electrogram of the local signal amplitude decreased by about 83% for CTP‒Ce6‒PEG 
and its targeting ability, after in vivo PDT treatment, was also confirmed by histology. 
In conclusion, all of these nanomatrices were designed to satisfy the basic 
requirements of a successful nanomatrix as described in Chapter 1; each was synthesized 
and engineered with its own advantages, as nanocarriers for multifunctional optical 
imaging and PDT of cancer, or for photo-ablation of cardiac arrhythmia by PDT.  
5.2 Future Directions 
In the next decades, heart and cancer diseases stand to benefit from the development 
of nanotechnology research. Our studies in this thesis demonstrated that PAA NPs and 
PEG nanoplatforms are promising delivery carriers for contrast agents of biomedical 
imaging and photo-drugs of PDT. Although these nanoplatforms consist of biocompatible 
and non-toxic materials, with facile fabrication, they have still a long way to go before 
they are ready for clinical and industrial applications. In here, a simple direction of 






 In Vivo Toxicity Tests of Nanoplatforms  5.2.1
The introduced nanoplatforms, PAA NPs and 8-arm PEG, were claimed as 
biocompatible and non-toxic materials for biomedical applications. For the PAA NPs, an 
in vitro toxicity test was given through CCK-8 assays in Chapter 2; the test was reported 
to demonstrate its non-toxicity towards several cell lines. Since the changing of chemical 
structure can cause toxicity to material, the toxicity of modified NPs was also tested after 
albumin conjugation or dye loading. However, a cellular level toxicity test spanning only 
1 – 3 days is not enough for justifying the safety of the application of such nanomaterials 
at the clinical level. Although PAA NPs were classified as bio-degradable NPs, due to the 
ester groups in their cross-linkers, a study reports that, under treatment with 1M NaOH, it 
took 1000 h to decrease the size of these NPs from 39.4 nm to less than 5 nm. [1] Since 
most of our body is around pH 7.4, the actual required time for degradation of NPs might 
be much longer, i.e., most of the PAA NPs may stay in our body for a long time without 
excretion. [2,3] Furthermore, the extremely small sized nanoplatform could penetrate 
practically anywhere in the human body, not only into the targeted area; this unwanted 
wide distribution of the nano-drug could lead to unexpected side effects. [4] To prevent 
such in vivo cytotoxicity, it would be needed to perform further research on the above 
nanoplatforms through animal testing. After adding various doses of nanoplatforms to an 
animal, its weight and health status can be checked over the course of several weeks. 
Then, each organ and tissue of the tested animal has to be analyzed for the amount of 
residual nanoplatforms, with confirmation of any injury to each organ. Based on the bio-
distribution, the nanoplatforms can be applied to various diseases of each organ, and the 




modified by the design of the biodegradable polymer or its cross-linker, towards fast 
excretion, which is one of the important factors in removing toxicity. [5] Also, the same 
test should be applied to large animals, such as pigs, monkeys or sheep. Such long term 
in vivo toxicity tests of nanoplatforms are needed for FDA approval of human clinical 
trials. Such tests would accelerate the commercialization of the PAA NPs or 8-arm PEG 
nanoplatforms.  
 Multifunctional (Theranostic) Modification of Nanoplatform 5.2.2
In Chapter 2, multimodal (photoacoustic and fluorescence) imaging techniques were 
successfully demonstrated from available ICG loaded NPs. With further development a 
superior nanoplatform would enable not only the detection of cancer but also treatment of 
cancer at the same time. It is already known that HSA is used as a delivery tool for 
chemo-drugs, like doxorubicin, dexamethasone, methimazole and paclitaxel. [6-9] To 
deliver these chemo-drugs, HSA‒PAA NPs can be applied to deliver both imaging 
contrast agent (ICG) and chemo-drugs, simultaneously. To optimize the loading of dyes, 
the optimal amount of HSA should be investigated first, by varying the amount of 
conjugated HSA. Although more HSA might help to load more dyes it also results in 
increasing the size of the NPs, which is limiting in certain therapeutic condition.  
Our group has also studied tumor delineation using Coomassie Blue (CB) loaded 
PAA NPs. [10,11] During brain cancer surgery, it is very important to visualize the tumor 
margins and, accordingly, covalently linked CB has been targeted to the tumor by using 
NPs with the aim of aiding the surgeon’s performance. Instead of CB‒PAA NPs, which 
are only useful for delineation, MB‒PAA NPs could be applied to both tumor delineation 




PEGDMA PAA NPs results in a very high absorbance and also in a relatively high ROS 
productivity due to superoxide production. From these results, tumor targeted MB–PAA 
NPs can be utilized to delineate the tumor boundaries (during surgery), i.e., to visually 
monitor the blue “painted” tumor due to the accumulation of these blue NPs, when 
targeted specifically to the tumor cells, and then, only the blue colored area can be treated 
by PDT to kill the tumor cells. [10-12] Furthermore, the same MB loaded NPs can also 
be used as sonophoric contrast agents for obtaining the 3-dimensional structure of the 
“blue” tumor by photoacoustic imaging, as demonstrated previously with CB–PAA NPs. 
[10] Additionally, these NPs could also serve as nano-regulators by mimicking ROS 
production during cellular metabolism. The highly localized ROS produced by these NPs 
could also be used to modulate intracellular signaling pathways, enabling refined and 
novel methods of cellular research. [13,14] Such “theranostic” modification of the 
nanoparticles will enable the realization of “multifunctionality” in the true sense of the 
word, so that several biomedical applications, based on chemotherapy, fluorescence, 
photoacoustic imaging, visual delineation and PDT will be carried out with a single kind 
of nanoplatform. This theranostic nanoplatform could be a solution towards decreasing 
the operational time of imaging and surgery. 
 Fast Degrading Photosensitizer for Selective Cardiac Ablation. 5.2.3
In Chapter 4, a novel photo-drug (CTP‒Ce6‒PEG) successfully ablated myocyte cells, 
both in vitro and in vivo. However, from the bioluminescence test on CTP‒Ce6‒PEG in 
rats, it was found that nanoplatforms accumulated in every organ, including the heart, 
lung, liver, pancreas, muscle, kidney and skin, (Figure 5-1). While photosensitizer 




serious side effects (“sun burns”) when accumulated in the skin, and especially in the 
eyes due to sunlight. The Ce6 is a hydrophobic photosensitizer and known to have pretty 
high stability in water (slow degradation). Instead of Ce6, MB could be the alternative 
answer for the photosensitizer. Though MB has a short half-life in the human body due to 
fast renal excretion and plasma enzyme enhanced reduction/isomerization (turning to 
leuko MB), conjugating with the bulky 8-arm PEG (40 kDa) could increase the 
circulation time in the plasma due to prevention of fast renal excretion and enhancement 
of the MB chemical stability. [15-17] However, the size of the 8-arm PEG (40kDa) is 
below the upper limit for kidney excretion and the 8-arm PEG cannot protect the MB 
perfectly from bio-enzymes, in contrast to PAA NPs which 3-dimensionally encapsulate 
MB. [16] Thus the MB‒8-arm PEG may be excreted or reduced to its lueko-MB form, 
within time periods of appropriate length. Last, so as not to be limited to rats, the in vivo 
study of these new photo-drugs, CTP‒Ce6‒PEG or CTP‒MB‒PEG, on larger animals 
(rabbits or sheep), will be investigated towards human clinical trials. Thus, the heart 
arrhythmia patient can get treatment with minimal side effects and risk related to the 
catheter ablation technique, through the use of a highly myocyte selective ablation PDT. 
Furthermore, based on this, this 8-arm PEG based photo-drug for PDT may be applicable 






Figure 5-1 Ex vivo fluorescence image of each of several organs, from a bioluminescence 
study. Each organ was excised from a rat, at 24 h post injection of 100 mg of CTP‒Ce6‒
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